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     Metabolic syndrome increases the risk of cardiovascular disease and diabetes. Th  
International Diabetes Federation (IDF) recently proposed new criteria for the diagnosis of 
metabolic syndrome, which requires the presence of central obesity as measured by ethnic 
specific waist circumference (WC) cutoff values. Currently, no specific WC thresholds for 
diagnosis of central obesity in Hispanics are available. The objectives wer  to determine the 
appropriate gender specific WC thresholds for diagnosis of central obesity in Mex can American 
adults and to estimate the prevalence of metabolic syndrome using IDF definition with and 
without the modified WC in this population. Data from 3265 Mexican American adults aged 20-
80 years who participated in the National Health and Nutrition Examination Survey 1999-2006 
were used. The prevalence of metabolic syndrome was compared using IDF criteria with and 
without the modified waist circumference. Receiver operating characteristic curve analysis 
suggested that yielding at least 80% sensitivity, the WC value of 90 cm in both genders was 
more appropriate in predicting the presence of two or more metabolic syndrome risk factors in 
  
this population. Based on this cutoff, there was 34% reduction in the prevalence of central 
obesity in women (82.5% to 54.2%). The age adjusted prevalence of metabolic syndrome 
decreased from 58.4 to 48.2%. The metabolic syndrome was more common among Mexican 
American men than women (55.8% in men versus 37.8% in women, P =0.0003). Our findings 
provided a practical guidance in the assessment and screening of central obesity and metabolic 
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Chapter 1: Introduction 
     Metabolic syndrome, the clustering of metabolic risk factors including central obesity, insulin 
resistance, atherogenic dyslipidemia, hyperglycemia, hypertension, prothrombotic and a 
proinflammatory condition is associated with increased risk of cardiovascular disease and type 2 
diabetes mellitus (1). This syndrome is one of the major medical and public health prob ems in 
the United States (2, 3) and worldwide (4-6). An estimated 47 million U.S. residents have 
metabolic syndrome and the age adjusted prevalence of syndrome is 23.7 percent (2). The 
prevalence ranges from 6.7 percent among people ages 20–29 to 43.5 percent for ages 60–69 and 
42.0 percent for those age 70 and older. Mexican Americans have the highest age adjusted 
prevalence of metabolic syndrome (31.9 percent). The lowest prevalence is among whites (23.8 
percent), African Americans (21.6 percent) and people reporting as “other” rac or ethnicity 
(20.3 percent) (7).  
     Subjects with metabolic syndrome have twice greater risk to die from and three times greater 
risk of having a heart attack or stroke, compared with people without the syndrome. 
Furthermore, people with metabolic syndrome have five fold larger risk of developing ty e 2 
diabetes (1). Coronary Heart Disease (CHD) is a major public health problem and the leading 
cause of death in the United States and worldwide (8).  In 2004, more than 15 million adults age 
20 and older had CHD and each year, more than half a million Americans die from this condition 
(7). Diabetes is one of the most common chronic diseases worldwide affecting almost 200 
million people and is the fourth leading cause of death in the developed countries (8).  
     In the effort of introducing the metabolic syndrome into clinical practice and identifying 
individuals with this condition, several sets of criteria have been proposed by different 




Resistance (EGIR), the American Association of Clinical Endocrinologists (AACE) and the 
National Cholesterol Education Program- Adult Treatment Panel III (NECP ATP III) have 
suggested some of the most accepted definitions (9-13). All of these definitions agree on the key 
elements of the metabolic syndrome including obesity, insulin resistance, hypertension and 
dyslipidemia; however they provide different criteria and cut points to define this cluster. The 
existence of several definitions was the main reason for proposing single unifying criteria by the 
International Diabetes Federation (IDF) in 2005, as a simple diagnostic tool for use in clinical 
practice and research worldwide. The IDF definition requires the presence of central obesity for 
diagnosis of metabolic syndrome. Central obesity is most easily measured by waist 
circumference (WC) with gender-ethnic specific thresholds (9). The current recommendations 
for defining central obesity in MAs (waist circumference ≥ 90 cm in men and ≥ 80 cm in 
women) are based on data from South Asia population and may not correctly estimate the 
prevalence of obesity in Hispanics due to ethnic differences in overall adiposity, abdominal 
adiposity and visceral fat accumulation (14-16). Studies on Asians have shown that for a given 
BMI or waist circumference, Asians had higher percentage of body fat when compared to 
Caucasians (17-19).  Findings from prospective study of 110 Hispanic and non-Hispanic white 
women revealed higher levels of adiposity and lower fat free mass in trunk region in Hispanic 
women (20).  
     Previous studies have shown a disproportionately high prevalence of diabetes in Hispanics 
compared to non-Hispanic whites. Hispanics are twice as likely to have diabetes s non-Hispanic 
whites of similar age. The prevalence of cardiovascular disease is also high in this population 
and is comparable to non-Hispanic whites (7). Hispanic population is the largest, fastt growing 




the number of U.S. born Hispanics with legal residents, temporary workers and those without
proper documentation would increase the total U.S. Hispanic population to 75 million (22). 
Recently Ford et al. (2002) reported that metabolic syndrome risk factors re very frequent in 
Hispanic men and women. Obesity is epidemic among this population and abdominal obesity is 
present in nearly 46% of Mexican Americans. MA also have a high incidence of other 
components of metabolic syndrome including: hypertriglyceridemia (37.7%), low levels of HDL 
cholesterol (39.6%), hypertension or being treated for blood pressure (36.6%) and hyperglycemia 
or taking medication for diabetes (20%)(2).  
     Central obesity is one of the main features in identifying individuals with metabolic 
syndrome. The association between obesity and the components of metabolic syndrome has been 
investigated by anthropometric measurements such as body mass index (BMI), waist to hip ratio 
(WHR) and waist circumference (23-26). Body mass index in Kg/m2, is a measure of overall 
obesity and provides estimation of total body fat with no further information on the distribution 
of excess fat storage. Waist to hip ratio measures abdominal fat accumulation, and has less 
power in predicting health risk factors when compared to waist circumference. Waist 
circumference reflects the amount of abdominal adipose tissue storage as well as total fat mass, 
providing a measure of body fat distribution. It also complements BMI in predicting obesity 
related diseases and health risks (24-26). Several studies have shown that waist circumference is 
a better predictor of metabolic abnormalities and cardiovascular disease risk factors than BMI 
(14, 15 and 26). 
     A proinflammatory state is frequently present in patients with metabolic syndrome and is 
recognized by elevated inflammatory markers such as interleukin-1, interleukin-6, tumor 




leukocyte count (27-29). CRP, an acute phase reactant produced by liver is the most studied 
biomarker of low grade inflammation and increases in response to infection, injury and chro ic 
inflammation. Physical activity, smoking, alcohol consumption, estrogen use, lipid lowering 
statin and anti-inflammatory medications have been documented to alter the CRP concentrations 
(29, 30). CRP distributions vary by gender and ethnicity (31-34). Previous studies have shown 
higher levels of CRP among women than men. Mexican American and Black individuals also 
have higher CRP concentrations when compared to Caucasians (35, 36). Several studies have 
found associations between higher levels of CRP and metabolic syndrome risk factors (37-39), 
cardiovascular disease (40-42) and diabetes mellitus (27, 43 and 44). 
     Considering the high incidence of metabolic syndrome, diabetes and CVD in Hispanic 
population, there is an urgent medical, ethical and economical need to identify individuals with 
this syndrome early, so that lifestyle interferences and treatment may prevent the development of 
diabetes and/or cardiovascular disease in this population. Few studies have investigated the 
association of abdominal adiposity, overall obesity and the components of metabolic syndrome 
in Mexican Americans (45) and little information is available on the CRP distribution and its 
relation with metabolic syndrome in this population. Most of the previous studies have focusd 
on non Hispanic Whites or non representative population samples (23-27, 34, 37 and 47). 
Therefore, using data from the National Health and Nutrition Examination Survey (NHANES) 
1999-2006, I focused primarily on determining the appropriate waist circumference cutoff values 
for diagnosis of central obesity in Mexican American adults and compared the prevalence of 
metabolic syndrome based on IDF definition with and without the modified waist circumference 
in Mexican Americans. I also examined the association between abdominal adiposity, measured 




of metabolic syndrome including, triglyceride, blood pressure, fasting plasma glucose and HDL 
cholesterol in Mexican American adults and investigated the odds for developing metabolic 
syndrome risk factors according to quartiles of waist circumference in this population. To study 
the final objectives of the dissertation, I investigated the distribution of CRP and its association 
with metabolic syndrome in Mexican Americans and estimated the odds ratios for developing 
metabolic syndrome or its components (central obesity, hypertriglyceridemia, hyperglycemia, 
hypertension and low HDL cholesterol) according to quartiles of CRP in this populati n.  
     To my knowledge, this is the first study to investigate the appropriate waist circumference 
cutoff values for diagnosis of central obesity and metabolic syndrome in Mexican American 
adults. In addition, it is the first study to examine the association between abdominal adiposity, 
overall obesity and CRP with the components of metabolic syndrome in Mexican American 
adults using 8 years of continuous NHANES 1999-2006 data. The findings of the present study 
are derived from a representative sample of Mexican American adults in the Unied States and 
are applicable to this population. The results from this study will provide practical guidance in 
identifying individuals with metabolic syndrome and contribute in understanding the association 





1. To determine the appropriate gender specific waist circumference cutoffvalues for the 
diagnosis of central obesity in Mexican American adults to predict increased risk of elevated 
triacylglycerol, reduced HDL cholesterol, elevated fasting plasma glucose, elevated blood 
pressure, or two or more of these factors. 
2. To compare the prevalence of metabolic syndrome in Mexican American adults using current 
IDF waist circumference and new WC determined in question 1. 
3. To investigate the relationship between CRP and the components of metabolic syndrome, in 
Mexican American adults. 
4. To estimate the odds ratios for developing metabolic syndrome and its components (central
obesity, hypertriglyceridemia, low HDLc, hyperglycemia and hypertension) in subjects with 
elevated CRP concentration. 
5. To examine the associations of overall obesity (measured by BMI) and abdominal adiposity 
(estimated by WC) in subjects with metabolic syndrome.  
6. To estimate the odds ratios for the development of metabolic syndrome and its components 
(central obesity, hypertriglyceridemia, low HDLc, hyperglycemia and hypertension) in 







1. What are the appropriate gender specific waist circumference cutoffs for diagnosing central 
obesity in Mexican American adults? 
2. What is the prevalence of metabolic syndrome in Mexican American adults using c rrent 
IDF waist circumference and new WC determined in question 1?  
3. What is the association between plasma CRP concentration and the components of metabolic 
syndrome in this population? 
4. What are the odds ratios for the development of metabolic syndrome and its components 
(central obesity, hypertriglyceridemia, low HDLc, hyperglycemia and hypertension) in 
subjects with elevated CRP concentration? 
5. What is the association between overall obesity (measured by BMI) and abdominal adiposity 
(measured by waist circumference) with the components of metabolic syndrome including, 
triglyceride, blood pressure, fasting plasma glucose and HDL cholesterol in Mexican 
Americans? 
6. What are the odds ratios for the development of metabolic syndrome and its components 
(hypertriglyceridemia, low HDLc, hyperglycemia and hypertensio ) n subjects with elevated 








     The combination of metabolic abnormalities now known as metabolic syndrome was first 
described by Kylin in 1923 as the clustering of gout, hypertension, and hyperglycemia (47). In 
1988 Reaven used the term syndrome X and established the clinical importance of this condition 
as concurrence of hypertension, hyperglycemia, glucose intolerance, elevated triglycerides, and 
low HDL cholesterol (48). This syndrome has also been termed as the deadly quartet, 
dysmetabolic syndrome X and insulin resistance syndrome by other scientists (49, 50).                                                      
     Metabolic syndrome (MetS) is the constellation of metabolic risk factors includ ng central 
obesity, atherogenic dyslipidemia, elevated plasma glucose, elevated blood pressure, 
prothrombotic and a proinflammatory state that increases the development of cardivascular 
disease and is associated with type 2 diabetes mellitus (1). 
     In the effort of introducing the metabolic syndrome into clinical practice, sev ral different 
sets of criteria have been proposed by different organizations for identifying pat ents with MetS. 
The more accepted of these definitions has been proposed by World Health Organization 
(WHO), the European Group for the Study of Insulin Resistance (EGIR), the American 
Association of Clinical Endocrinologists (AACE) and the National Cholesterol Education 
Program- Adult Treatment Panel III (NECP ATP III) (9-13).  
     The World Health Organization (WHO) definition for MetS emphasizes insulin resistance as 
the major underlying risk factor and requires its evidence for diagnosis. The presence of one of 
the several markers of insulin resistance and at least two risk factors amng obesity, 
hypertension, high triglycerides, reduced HDL cholesterol and microalbuminuria constitutes a 




setting and field studies, therefore different markers of indirect evidence were accepted, i.e., 
impaired glucose tolerance (IGT), impaired fasting glucose (IFG), type 2 diabetes mellitus, or 
impaired disposal of glucose under hyperinsulinemic, euglycemic conditions. The WHO group 
allows the term metabolic syndrome to be used in patients with type 2 diabetes who met t e
requirements for this syndrome. They justified that patients with type 2 diabetes m llitus are at 
higher risk for cardiovascular disease (10). 
     In 1999 the European Group for the Study of Insulin Resistance (EGIR) defined the syndrome 
in non-diabetic individuals who have hyperinsulinemia, which is simpler to use in 
epidemiological studies, since it does not require measurement of  insulin sensitivity. EGIR 
proposed to use fasting insulin levels to estimate insulin resistance and impaired fasting glucose 
as a surrogate for IGT. By their criteria, plasma insulin levels in the upper quartile of the 
population will define insulin resistance. Elevated fasting plasma insulin plus 2 other factors 
including abdominal obesity, hypertension, increased triglycerides, decreased HDL cholesterol 
and increased fasting plasma glucose will define metabolic syndrome. They also modified the 
threshold for triglycerides, hypertension, and HDL cholesterol and used waist circumfe ence as a 
measure of central obesity. Further, if subjects were receiving treatment for hypertension or 
dyslipidemia they were considered to have the risk factor (11).  
     In 2001 the National Cholesterol Education Program (NCEP), Adult Treatment Panel III 
(ATP III) proposed alternative clinical criteria for defining metabolic syndrome. The definition is 
based on WHO criteria and requires the presence of at least three of five components including 
elevated triglycerides, reduced HDL cholesterol, hypertension, elevated fasting glucose and 
central obesity (highly correlated with insulin resistance). It does not include any measure of 




practice. The criteria do not emphasize a single cause and includes waist circumference as the 
measure of obesity (12). The cut points for central obesity adopted from 1998 National Institute 
of Health obesity clinical guideline were waist circumference ≥102 cm (≥40 inch) for men and 
≥88 cm (≥35 inch) for women (51). These cut points represent the upper quartile of the US 
population. As some individuals of other ethnic groups i.e., South Asians and Chinese are 
susceptible to develop metabolic syndrome at lower waist circumference, The ATP III noted that 
individuals who have only 2 metabolic criteria can manifest characteristics of metabolic 
syndrome even when the waist circumference is marginally elevated, for example 94-101 cm in 
men or 80-87 cm in women. If so, they should be treated similarly to those who have higher 
waist circumference plus two other risk factors. ATP III, like WHO allows the term metabolic 
syndrome to be used in patients with type 2 diabetes because of higher risk of cardiovascular 
disease among these patients (12). Few years later, the ATP III announced some clarifications in 
metabolic syndrome definition including using lower waist circumference thresholds for ethnic 
groups who are susceptible for insulin resistant, counting the medication use for high 
triglyceride, low HDL and high blood pressure as the risk factor for these conditions even when 
their values are normal, and reducing the blood glucose thresholds for hyperglycemia from 110 
mg/dl to 100 mg/dl (1). 
     In 2003 the American Association of Clinical Endocrinologists (AACE) releas d  position 
statement on insulin resistance syndrome. Major factors for identifying the syndrome are 
elevated triglycerides, reduced HDL cholesterol, elevated blood pressure, obesity and elevated 
fasting and post load glucose. The AACE statement does not provide a specific number of 
factors for definition of syndrome and allows the diagnosis to rely on clinical judgment. Other 




polycystic ovary syndrome and hyperuricemia. By this definition the term “insulin resistance 
syndrome” can be applied until the person is diagnosed with type 2 diabetes (13).  
     In 2005, the International Diabetes Federation (IDF) proposed new criteria that modify ATP 
III definition. This definition requires the presence of abdominal obesity for diagnosis of 
syndrome. The rationale for this requirement is that abdominal obesity is highly correlated with 
insulin resistance and other components of the syndrome. They introduced a simple diagnostic 
tool for use in clinical practice and research worldwide. The definition would allowcomparison 
of the prevalence of the syndrome in different populations and its association with various health 
consequences. “According to IDF definition, for a person to be defined as having the metabolic 
syndrome, they must have the central obesity plus any two of the four additional factors. These 
factors are: 
• Elevated triglycerides level: ≥ 150 mg/dl (1.7 mmol/l) or specific treatment for this lipid 
abnormality 
• Reduced HDL cholesterol level: < 40 mg/dl (1.03 mmol/l) in men and < 50 mg/dl (1.29 
mmol/l) in females or specific treatment for this lipid abnormality 
• Elevated blood pressure: systolic BP ≥ 130 or diastolic BP ≥ 85 mmHg or treatment of 
previously diagnosed hypertension 
• Elevated fasting plasma glucose: FPG ≥ 100 mg/dl (5.6 mmol/l) or previously diagnosed 
type 2 diabetes” (9). 
 
     IDF emphasized the use of gender-ethnic specific values for waist circumference when 
measuring central obesity, as there are clear differences across ethnic populations between 
overall adiposity, abdominal adiposity and visceral fat accumulation (14, 15). For Europids the 




in women. These thresholds are based on cross sectional studies in European countries and are 
the best values for identifying overweight people, defined as BMI of ≥25 kg/m2 or WHR ≥0.90 
for men and ≥0.85 for women (52). For Asian populations, the cut points are ≥90 cm in men and 
≥80 cm in women (22, 53-57).  
     All definitions agree on the key elements of the MetS including obesity, insulin resistance, 
hypertension and dyslipidemia. However they provide different criteria and cut points to define 
this condition. The different criteria proposed for clinical diagnosis of metabolic syndrome are 

















IGT, IFG, T2DM and/or 
insulin resistance Plus 2 or 
more of the following 
Fasting plasma insulin > 
75 percentile for non-
diabetic individuals Plus 2 
or more of the following 
None 
Any of the 3 following 
IGT or IFG Plus any of 




Men: WHR >0.90 
Women: WHR>0.85 
and/or BMI>30 kg/m2 
Men: WC ≥94 cm 
Women: WC ≥80 cm 
Men: WC ≥102 cm 
Women: WC ≥88 cm 
BMI ≥25 kg/m2 
Central obesity defined as 
WC with ethnic specific 
cutoffs plus 2 or more of 
the following 
Triglycerides TG ≥150 mg/dl 
TG >180 mg/dl and/or 
medication use for 
dyslipidemia 
TG ≥150 mg/dl TG ≥150 mg/dl 
TG ≥150 mg/dl or specific 
treatment for dyslipidemia 
HDLc Men: <35 mg/dl Women: <39 mg/dl 
HDLc <39 mg/dl and/or 
medication use for 
dyslipidemia 
Men: <40 mg/dl 
Women: <50 mg/dl 
Men: <40 mg/dl 
Women: <50 mg/dl 
Men: <40 mg/dl 
Women: <50 mg/dl or 
specific treatment for 
dyslipidemia 
Fasting glucose IGT, IFG or T2DM ≥ 110 mg/dl ≥ 110 mg/dl IGT or IFG (Not diabetes) 
≥ 110 mg/dl or previously 
diagnosed T2DM 
Blood pressure ≥ 140/90 mmHg 
≥ 140/90 mmHg and/or 
medication use for 
hypertension 
≥ 130/85 mmHg ≥ 130/85 mmHg 
≥ 130/85 mmHg or 
treatment for hypertension 
Other  Microalbuminuria   
Family history of CVD or 




BMI, body mass index; CVD, cardiovascular disease; HDLc, high density lipoprotein cholesterol; IGT, impaired glucose tolerance; IFG, impaired fasting 
glucose; T2DM, type 2 diabetes mellitus; WHR, waist to hip ratio; WC, waist circumference. 
*In 2004, the NCEP ATP III definition had some clarifications including using lower WC cutoffs for ethnic groups who are susceptible for insulin resistance, 






Characteristics of Metabolic Syndrome  
General features of metabolic syndrome are summarized as: 
 
Abnormal body fat distribution 
     Central or abdominal obesity is one of the main features of metabolic syndrome and is 
independently correlated with all other components of the syndrome. Central obesity contributes 
to insulin resistance, hypertension, dyslipidemia and hyperglycemia and is associated with 
increased risk of cardiovascular disease and type 2 diabetes mellitus independent of ov rall 
adiposity (58-62). Waist circumference reflects the amount of abdominal adipose tissue deposits 
as well as total fat mass, providing a measure of body fat distribution. It also complements body 
mass index in evaluation of obesity related health risk (24-26). Several studies have shown that 
in assessment of abdominal adiposity waist circumference is complementary or superior to body 
mass index (14, 15 and 26). When measuring central obesity, gender-ethnic specific values for 
waist circumference should be used, since there are clear differences in overall adiposity, 
abdominal adiposity and visceral fat accumulation among ethnic populations (14, 15). 
Insulin resistance 
     Insulin resistance is the condition in which liver, skeletal muscle and adipose tissu  cells 
become less sensitive and eventually resistant to insulin. Insulin resistance in fat cells results in 
hydrolysis of stored triglycerides and increases of free fatty acidsin the blood. In muscle, insulin 
resistance reduces glucose uptake whereas in liver it reduces glucose storag , both would cause 
an increase in blood glucose. Insulin resistance is present in most people with metabolic 
syndrome. It is strongly associated with some metabolic risk factors; however its association 




commonly seen in individuals with metabolic syndrome (63) and studies have shown that upper 
body adiposity is strongly associated with insulin resistance. Excess upper body fat can be 
accumulated as intraperitoneal (visceral) or subcutaneous (truncal) fat. Results from several 
studies suggest that excess visceral fat is more strongly correlated with insulin resistance than 
any other adipose tissue compartment (64-66); other researchers claim that excess subcutaneous 
abdominal fat has a significant association with insulin resistance (67-69). In general the pattern 
of upper body adiposity (abdominal obesity) correlates more strongly with insulin resistance and 
the components of metabolic syndrome than lower body obesity (1). Elevated circulating free 
fatty acids are important factor which links upper body adiposity and insulin resistance (70, 71).  
Atherogenic Dyslipidemia 
     The dyslipidemia found in individuals with metabolic syndrome is multi-factorial, and is 
associated with a cluster of interrelated cardiovascular disease risk factors. Lipoprotein 
abnormalities including increased triglycerides and apo lipoprotein B, reduced HDL cholesterol, 
increased small dense LDL particles and increased small HDL particles are main features of 
atherogenic dyslipidemia. Variations in the pattern and magnitude of the dyslipidemia are due to 
the interaction of genetic factors with environmental influences including diet, physical activity 
and stress. All of these lipid abnormalities are independently atherogenic (1, 9). The lipid 
abnormalities in metabolic syndrome are related to insulin resistance and some mediators like 
lipoprotein lipase, hepatic lipase and cholesterol ester transfer protein (72-74). 
Hypertension 
     Elevated blood pressure is a medical condition in which the blood pressure is chronically 
increased. Persistent hypertension is one of the risk factors for strokes, heart attacks, heart failure 




essential hypertension, no specific medical cause can explain a patient's condition. In secondary 
hypertension the high blood pressure is caused by another condition, such as kidney disease or 
adrenal gland tumor (75). Elevated blood pressure is associated with obesity and glucose 
intolerance and insulin resistance. The strength of this relation varies in different populations (9, 
76). 
Proinflammatory State 
     A proinflammatory state is frequently present in patients with metabolic syndrome and is 
recognized by elevated inflammatory markers (27, 28). In general a proinflammatory state can be 
characterized by determining proinflammatory risk factors such as oxidized LDL cholesterol, 
proinflammatory cytokines (e.g., interleukin-1, tumor necrosis factor-α), adhesion molecules 
(e.g., intercellular adhesion molecule-1, selectins), inflammatory stimuli with hepatic effects 
(e.g., interleukin-6) or the products of the hepatic stimulation, such as serum amyloid A (SAA), 
C-reactive protein (CRP), and other  inflammation factors, such as elevated leukocyte count (29). 
According to American Heart Association (AHA) and Centers for Disease Control and 
Prevention (CDC) scientific statement on “Markers of Inflammation and Cardiovascular 
Disease”, C-reactive protein (hs-CRP) is the first choice if inflammatory markers need to be 
measured. Recent studies have shown that elevated CRP level is strongly associated with 
components of metabolic syndrome. CRP is an acute phase reactant produced by liver and will 
increase dramatically in response to infection, injury and inflammation (31). CRP should be 
measured in metabolically stable patients without known inflammatory or infectious conditions 
to decrease intra individual variability, and the assessment should be repeated in 2 weeks and the 
average of the 2 measurements should be used. Serum hs-CRP levels <1.0 mg/L are defined as 




cardiac events, corresponding approximately to tertiles of the adult population. Serum CRP level 
greater than 10 mg/L is an indicator of ongoing infection, acute illness or injury (29). 
Prothrombotic State 
     A prothrombotic state is a feature of metabolic syndrome and is characterized by an increase 
in plasminogen activator inhibitor-1(PAI-1), fibrinogen, tissue factor and factor VII and a 
decrease in tissue plasminogen activator activity. PAI-1 is a marker of r duced fibrinolytic 
capacity and is strongly associated with components of metabolic syndrome (9, 38 and 77).  
Prevalence of Metabolic Syndrome 
     Metabolic syndrome is one of the major medical and public health problems in the United 
States (2, 3) and worldwide (4-6). An estimated 47 million U.S. residents have metabolic 
syndrome (7). The age-adjusted prevalence of this syndrome for adults is 23.7 percent (2). The 
prevalence of syndrome rises with age. Analysis of data on 8814 nationally representative non-
institutionalized US population aged 20 years or older from Third National Health and Nutrition 
Examination Survey revealed that metabolic syndrome prevalence is highly correlated with age, 
increasing from 6.7% in individuals aged 20-29 years to over 40% in individuals aged ≥ 60 years 
(2). Another study showed that metabolic syndrome reaches its peak levels in the 60s for men 
and 70s for women (78). The prevalence of the syndrome increases significantly with increasing 
BMI. Results from NHANES III revealed that metabolic syndrome was evident n 4.6% of 
normal weight, 22.4% of overweight and 59.6% of obese men. A comparable distribution was 
observed in women (77, 78). Metabolic syndrome prevalence varies by sex and ethnicity (2, 78). 
In the analysis of NHANES III, Park et al. (78) found the lowest prevalence in black men 
(13.9%) and the highest in Mexican American women (27.2%). Ford et al. reported the highest 




Americans (21.6%) and individuals from “other” ethnicity. The prevalence of metabolic 
syndrome was similar in men and women among whites and people from “other” ethnicity. 
African American women had about 57% higher prevalence than men and Mexican American 
women had about 26% higher prevalence compared to men (3). 
Pathogenesis of Metabolic Syndrome 
     The pathogenesis of metabolic syndrome and its components is multifaceted and continues to 
challenge the professionals. The underlying risk factors for developing this syndrome appear to 
be abdominal obesity (63, 78) and insulin resistance (48, 79). Other related risk factors are 
genetic profile (1, 80), aging (2), physical inactivity (78, 81) and hormonal imbalance (82).  
     The hypotheses relating central obesity to metabolic syndrome focus on adipose tissue 
(particularly visceral adipose tissue) hormonal role and secretion of adipokines (cytokines) and 
other bioactive substances such as free fatty acids. Adipose tissue actively secr tes large numbers 
of hormones and adipokines including leptin, adiponectin, tumor necrosis factor α (TNFα), 
interleukin 6 (IL-6), monocyte chemotactic protein 1, inducible nitric oxide synthase (iNOS), 
transforming growth factor β1, plasminogen activator inhibitor 1 (PAI-1) and resistin. These 
adipokines have autocrine, paracrine and endocrine actions for controlling different metabolic 
functions (37, 38 and 83). The expanding adipose tissue also discharges high levels of FFA into 
the portal and systemic circulation (71, 84 and 85); this may result in accumulation of lipid in
areas other than adipose tissue or ectopic fat storage syndrome. In muscles and liver, i creased 
FFA will promote insulin resistance (86, 87) and dyslipidemia (88). FFAs decrease insulin 
sensitivity in muscle by inhibiting insulin signaling, glucose phosphorylation, glyco en synthase 
and pyruvate dehydrogenase (89, 90). In the liver, FFAs promote glucose production (due to 




density lipoproteins (VLDL) since high amounts of glucose and FFA are available. Other lipid 
abnormalities include a decrease in high density lipoprotein (HDL), an increase in int rmediate 
density lipoprotein (IDL), low density lipoprotein (LDL), and production of small dense LDL 
(90).   
     Obesity is correlated with an inflammatory response which is characterized by abnormal 
adipokines production and activation of some proinflammatory pathways resulting in 
overproducing of several inflammatory markers (38, 83). Recent data indicate that obese adipose 
tissue is infiltrated by macrophages, which are responsible for the most part ofthe l cally 
produced TNFα and large amounts of IL-6 and inducible nitric oxide synthase expression (91, 
92). Adipose tissue TNFα increases adipocyte lipolysis, partly through its effects on perilipin 
(86, 87). “Perilins are phosphoproteins found in adipocytes on the surface of triacylglycerol 
droplets that act as gatekeepers, preventing lipases from hydrolyzing triacylglycerol to facilitate 
the release of FFAs.”(37). Therefore, TNFα may increase insulin resistance by promoting the 
fatty acid release from adipose tissue into the portal and systemic circulation (93, 94).  
     IL-6 production by adipose tissue is also increased in obesity (95, 96). In obese individuals 
the IL-6 expression is 10 fold than in lean individuals when normalizing for the number of 
current adipocytes. IL-6 increases lipolysis and fat oxidation in humans (97), it rises plasma 
concentration of fibrinogen, PAI-1 and CRP (98) and recently has been suggested to play an 
important role in the link between obesity, inflammation and coronary heart disease. 
Overproduction of IL-6 by adipose tissue could directly alter liver metabolism by inducing 
VLDL secretion and hypertriglyceridemia, since visceral adipose tisue (VAT) is closely 




     Plasminogen activating inhibitor-1 is an important factor in the maintenance of vascular 
homeostasis, regulating thrombus formation by inhibiting the activation of plasminogen and 
impairing fibrinolysis (100-102). PAI-1 is synthesized in liver and adipose tissue. The serum 
concentrations of PAI-1is increased in visceral adiposity and decreased in calor c restriction, 
change in dietary composition, weight loss, physical training and use of oral antidiabetic 
medications such as metformin (102-104). Visceral fat tissue secretes significantly more PAI-1 
than subcutaneous abdominal or femoral fat tissue (105, 106). The mechanisms connecting PAI-
1 to metabolic syndrome are complex and interrelated. Several inducers including etopic fat 
depot, TNFα, cortisol, renin angiotensin system and the oxidative and hypoxic stress may 
function together at different sites of synthesis (107-111). 
     Leptin, the first adipocyte hormone identified, is involved in regulating food intake and 
energy expenditure through a direct effect on hypothalamus. The relation between leptin and the 
low grade inflammatory state in obesity has been suggested by many studies(37, 99), implying 
that leptin can exert peripheral biological effects due to its cytokine like structure (112). It also 
can modulate TNFα production and macrophages activation. However, the underlying 
mechanisms have not been clearly determined (113). 
     Adiponectin or adipose most abundant gene transcript 1 (APM1) is an adipose tissue 
collagen like protein and has anti-atherogenic and anti-inflammatory effects (114). This hormone 
increases insulin sensitivity in muscles and liver, enhances FFA oxidation in different tissues, 
including skeletal muscle, promotes glucose utilization in muscles and reduces serum FFA, 
glucose and triglyceride level (37, 101 and 115). Additionally adiponectin may control the 




partly explain its anti-inflammatory and anti-atherogenic effect (116). The levels of circulating 
adiponectin are decreased in obesity, diabetes and insulin resistance (117-119).  
     Resistin, a 114 amino acid polypeptide hormone, was first discovered in 2000 by Steppan and 
colleagues (120). It is also called FIZZ3 (found in inflammatory zones) and originally proposed 
as a link between adipose tissue, obesity and insulin resistance. This hormone is primar ly 
secreted by adipocytes in rodents and in humans is mainly derived from immune competent cells 
such as monocyte and macrophages (121). Review of the literature on physiological role of 
resistin in rodent and human models has shown several discrepancies (122-125). In rodents 
resistin has an important role in development of liver insulin resistance; however in humans its 
role as an insulin resistance inducing factor is less determined and is more involv d in the 
regulation of inflammation. Recently, Lehrke et al. reported that resistin may have a role as a 
pro-inflammatory factor in healthy humans (126).   
     Many studies indicate that insulin resistance is an important factor in the development of 
obesity, metabolic syndrome and diabetes; however the mechanisms linking insulin re istance 
and other components of metabolic syndrome is not well understood (1, 9). Elevated level of 
circulating free fatty acids is an important factor that links obesity, dyslipidemia and insulin 
resistance (90, 127). The expanding adipose tissue discharges high levels of FFA into the portal 
and systemic circulation (71, 84 and 85); this will result in accumulation of lipid in areas other 
than adipose tissue and the ectopic fat storage syndrome could occur. In muscles and liv r, 
increased FFA will promote insulin resistance (86, 87) and dyslipidemia (88). These FFAs 
decrease insulin sensitivity in muscle by inhibiting insulin signaling, glucose phosphorylation, 
glycogen synthase and pyruvate dehydrogenase (89, 90). Increased cytokine production in 




that cytokines such as TNFα and IL-6 are involved in insulin resistance and its complications 
(128-130). Although the mechanisms have not been clearly determined, it could be related to 
tyrosine phosphatase activation (99) or an interaction between suppressor of cytokine signaling 
(SOCS) proteins and the insulin receptor (128, 129). 
     Several researches have suggested that gene ic background is an important factor in 
developing metabolic syndrome and its components (131, 132). Findings from twin and family 
studies confirm this genetic contribution (133- 136). Carmelli et al. in study of 2508 male twin 
pairs in the U.S. reported that clustering of hypertension, diabetes and obesity was found in 
31.6% of monozygotic pairs and only in 6.3% of dizygotic pairs (137). Comparable results for 
heritable factors were found in a female twin study (133). Candidate geneshav  been identified 
for key components of metabolic syndrome with single or multiple effects on syndrome 
components. For example variation in ADIPOQ that encodes adiponectin, has been associated 
with visceral obesity, diabetes, hypertension and dyslipidemia (138-140). The AGT variation 
which encodes angiotensinogen has been associated with blood pressure (141) and blood lipid 
concentrations have been related to variations in the APOE and APOC3 genes encoding 
apolipoproteins E and CIII, respectively (142, 143). In addition, variations in genes encoding 
FOXC2 and SREBP1 have been associated with insulin sensitivity and plasma triglycerides 
(144, 145). More research is needed to identify the genomic DNA markers that can be used 
clinically in the diagnosis and /or treatment of metabolic syndrome (132).  
     Aging has an important role in pathogenesis of metabolic syndrome since most of the 
metabolic syndrome components including obesity, hypertension and glucose intolerance are 
associated with aging. Many studies have shown an increase in prevalence of metab lic 




from Third National Health and Nutrition Examination Survey, Ford et al. observed that 
metabolic syndrome was prevalent in 6.7% of individuals aged 20-29 years, 43.5% of individuals 
aged 60–69 years and 42.0% of those age 70 and older (2, 146). Recent studies have shown 
psychosocial risk factors such as depression, anxiety, inadequate emotional support and negative 
life events are associated with a higher prevalence of metabolic syndrome in ld r people (148). 
Furthermore, a decrease in circulating androgen levels including lower total testosterone and low 
sex hormone binding globulin (SHBG) level can predict the development of metabolic syndrome 
and type 2 diabetes mellitus in middle aged and older men (146, 149). 
      Physical inactivity is another important factor in pathogenesis of metabolic syndrome. 
Numerous studies have examined the link between physical activity, fitness and metabolic 
abnormalities (150-154). Almost all studies reported that the levels of physical activity are 
inversely associated with the prevalence of this syndrome. Findings from epidemiological and 
intervention studies suggest that exercise training can reduce body weight and visceral fat 
accumulation (154, 156), improve insulin sensitivity (155-157), promote HDL cholesterol, 
decrease triglyceride and blood pressure levels (158, 159). The favorable effect of physical 
exercise on insulin sensitivity can be linked to changes in insulin signaling pathway in response 
to muscle contraction, for example increase in GLUT4 glucose transporters t he cell surface 
(160, 161). This effect is short term and will last 48-72 hours. Thus to maximize the benefits of 
physical training on insulin sensitivity, a daily activity is recommended (159). 
     Hormonal imbalances including hypercortisolemia, sex steroids and growth hormone 
deficiencies are important in pathogenesis of metabolic syndrome (1, 82 and 162). In 1992, 
Björntorp proposed that these hormonal insufficiencies may promote triglyceride deposition in 




Many studies have shown the high prevalence of metabolic syndrome in women and adolescent 
girls with polycystic ovary syndrome (PCOS). The PCOS is the most common cause of women 
infertility due to anovulation in the United States and around one-third to one-half of all wmen 
and adolescent girls with PCOS has the metabolic syndrome and increased risk of CVD and/or 
diabetes (82, 163 and 164). 
 
The Hispanic or Latino Population (Hispanic versus Latino) 
 
     The terms Hispanic and Latino have often been used interchangeably in the literature, but in 
fact are not corresponding to the same population. The term “Hispanic” comes from the Latin 
word for “Hispania” or “Spain”. It refers to people who were born in of the Latin America 
countries and Spanish is their primary language (except Brazil which Portuguese is the primary 
language). The word “Latino” is a broader term and refers to people who were born in a cou try 
where a Latin language is spoken. This term applies to individuals coming from countries in 
Latin America and even some in Europe such as France, Portugal, Spain, Italy, Alb nia and 
Romania (21). According to CDC “Hispanics or Latinos are persons of Cuban, Mexican, Puerto
Rican, South or Central-American, or other Spanish culture or origin, regardless of race” (165). 
In this research term Hispanic/Latino will be used, trying to be consistent with CDC definition. 
 
Hispanics/Latinos in the United States 
 
Demographics: The Hispanic/Latino population is the largest, fastest growing minority group in 
the United States, representing 14% of the total population. According to the 2006 U.S. Census 
Bureau population estimate, there are nearly 42.6 million Hispanics living in the United States 
(166). This population’s growth rate is four times that of the total population and it is est mat d 




Hispanics are a diverse population. In 2004, the largest Hispanic subgroups in the country were 
Mexicans (66%), followed by Central and South Americans (13%), Puerto Ricans (9.4%), 
Cubans (3.9%) and people of other Hispanic Origins (7.5%). The 10 states with the largest 
Hispanic/ Latino populations are California (12.5 million), Texas (7.8 million), Florida (3.4 
million), New York (3 million), Illinois (1.8 million), Arizona (1.6 million), New Jersy (1.3 
million), Colorado (0.89 million), New Mexico (0.82 million) and Georgia (0.62 million)(167-
169).  
     Unfortunately, these figures do not reflect the total number of Hispanics in the country as they 
are not accounting for an estimated 11.5 to 12 million unauthorized immigrants who live in the 
United States. According to Jeffrey S. Passel, Senior Research Associate of the Pew Hispanic 
Center, “the number of unauthorized migrants living in the United States has continued to 
increase steadily for several years, reaching an estimated 11.1 million based on the March 2005 
compared to an estimate of 8.4 million based on Census 2000”. In 2005, Mexicans were the 
largest unauthorized immigrants entering the country at 6.2 million (56%), while 2.5 million 
undocumented immigrants (24%) were from the rest of Latin America countries, mainly from 
Central America (170). 
     According to American Community Survey for Hispanics (171), the average age of Latinos in 
U.S. is about 13 years younger than the non-Hispanic White population (26.9 vs. 40.1 years). 
The average age for Latinos is also younger than that of the total U.S. population for men (26 vs. 
34 years) and women (27 vs. 36 years)(165).The Hispanic population has a larger percentag  of 
young people and a smaller percentage of older people when compared to non- Hispanic Whites. 
About 80% of Latinos are 24 years or younger and 1 in 3 Hispanics are 18 years old or younger, 




compared with about 15 percent of non-Hispanic Whites. Among the Hispanic-origin subgroups, 
Mexicans have the lowest median age, 25.3 years, and Cubans have the highest, 40.6 years 
(171). The gender distribution for Latinos is 50% males and 50% females, which is similar to 
the gender distribution for the total U.S. population (51% and 49%, respectively).  
     Latinos as a group tend to be married. In 2000, 52% of Latinos were married compared to 
33% never married, 4% widowed and 11% separated or divorced. They comprise 12% of 
households in the U.S. Fifty-one percent of Latinos live in households that consist of 3 to 5 
people. Eighteen percent live in households that include non-relatives compared with 11% of the 
total U.S. population.  
     Socioeconomic status can be defined as a function of different variables such as income, 
occupation and education. The U.S. Census Bureau has set a poverty threshold, which is defined 
as a function of the family size. Since Latinos have larger households compared to th  total U.S. 
population, different thresholds should be set for them to make comparisons. Only 29% of 
Latinos earn $50,000 or more compared with 49% for the total U.S. population. The percentage 
of Latinos whose annual income is less than $10,000 is also larger than that for the total 
population. The average income when measured by the number of family members is $26,641 
for U.S. population and $15,415 for Latinos. According to U.S. Census, the percentage of 
Latinos below the poverty level was 27% in 2000, which is a larger figure compared to the total 
population (172).  
     According to 2000 U.S. Census, 60% of the total U.S. population was employed in 
managerial and technical, sales, and/or administrative jobs, comparing to 61% of Latin s who 
are mainly engaged in service, industrial and agricultural jobs. There are some differences within 




managerial, technical, sales, and administrative support jobs than do other groups such as Puerto 
Ricans and Cubans, though they have higher employment in labor and farm occupations. 
     There are significant gaps in educational attainment rates when comparing Latinos and the 
total U.S. population.  In 2000, the proportion of Hispanics with only a fifth grade education ws 
17 times larger than that of non-Hispanic Whites (0.6% for NHW). According to 2004 U.S. 
Census, 58.4% of Hispanics in comparison to 85.8% NHW had a high school diploma and 
12.1% of Hispanics in comparison to 28.2% of NHW have a bachelor’s degree (166). When 
looking at educational attainment by gender, more women have an advantage of having high 
school diploma and college level education compared to men. The school drop-out rate is 
significantly higher for Latinos who were born outside of the United States. In 1997, the drop-
out rate for this group was much higher compared to individuals who were born in the United 
States but whose parents were born outside the United States (39% vs. 15%)(172).  
     Hispanic/Latino health status is affected by different factors such as language/cultural 
barriers, lifestyle behaviors, access to preventive health care services and health insurance 
coverage. When compared with other ethnic groups, Latinos have the second lowest death rates 
in the United States (601 per 100,000 deaths). According to the Centers for Disease Control and 
Prevention the 10 leading causes of death among Hispanics in 2001 were: heart disease, cancer, 
unintentional injuries (accidents), stroke, diabetes, chronic liver disease and cirrhosis, homicide, 
chronic lower respiratory disease, pneumonia & influenza and birth defects (173). There are 
clear differences in leading causes of death among Latinos and the total U.S. population as well 
as non-Hispanic Whites. These differences are in accident rates, liver diseases, homicides, and 
birth defects. Accidents are the third cause of death for Latinos and fifth for the t tal U.S. 




considered the leading cause of death for the total U.S. population or for non-Hispanic Whites. 
Some of these differences may be related to the different number of younger and older 
population among Latinos when compared with the total U.S. population. Also, recent 
immigrants can be at increased risk for chronic disease and injury, particularly if they are not 
fluent in English, familiar with U.S. health care system or have different cultural attitudes like 
preferring traditional medicine to conventional medicine (172, 173).  
     Over one third of Hispanic adults does not have health insurance coverage and 59% of 
those, personally know someone who is uninsured (174). Despite the fact that Hispanics are the 
largest ethnic minority population in the country, they are underserved by the health care system. 
Hispanics are less likely to seek and receive health care services, especially reventive services, 
which might contribute to their poorer health status and higher rates of morbidity an  mortality. 
In the analysis of Behavioral Risk Factor Surveillance System (BRFSS) surveys 2001-2002 data, 
considerable differences in prevalence of health care coverage were documented among 
Hispanics compared with non-Hispanics. These differences remained significant even after 
adjusting for health status and socioeconomic factors (175). 
     In this country access to health care is related to insurance coverage, the type of insurance, 
and whether a person has a regular source of care (176). The lower prevalence of health care 
access among Hispanics might be explained by disparities in receiving preventiv  services. 
Hispanic adults in the BRFSS were less likely than non-Hispanic adults to receive blood 
cholesterol and cancer screenings. Hispanics’ effort to obtain health insurance and health care 
services have been compromised by Language barriers, cultural practices, beli fs and the 




    Associations between mortality and socioeconomic factors including education, occupation 
and employment, health insurance and poverty have been reported. Despite higher poverty ates, 
less education attainment and worse access to health care, for most Hispanic groups living in the 
United States, health and mortality outcomes are equal to or better than non Hispanic whites 
(178, 179). This phenomenon is known as “Epidemiological Paradox” or “Hispanic Health 
Paradox”. Some potential explanations for this multifactor paradox are: under-reporting and/or 
misclassification of Hispanic deaths, Salmon bias and healthy migrant effects. The Salmon bias 
hypothesis suggests that Hispanics are returning to their origin country after they retire or 
became seriously ill. The healthy migrant effect hypothesis is “based on the notion that the 
strongest and healthiest members of a population migrate”. Th  paradox does not hold equally 
for all Hispanic subgroups. Morales et al. in the review of social, economic and behavioral 
determinants of health for Hispanics in the United States observed that, the heal par dox exists 
most strongly in Mexicans but does not appear to hold for Puerto Ricans (178, 179).  
 
Metabolic Syndrome in Hispanics 
 
     Mexican Americans have the highest age-adjusted prevalence of metabolic syndrome 
(31.9%), when compared to whites (23.8%), African Americans (21.6%) and individuals from 
“other” ethnicity (20.3%).  In Mexican Americans the syndrome is more prevalent among 
women (26% higher) than men (7). In 2003, Meigs et al. (180) compared the prevalence and 
characteristics of metabolic syndrome among non Hispanic White (NHW) and Mexican 
American (MA) subjects participating in San Antonio Heart Study (SAHS) phase II follow up 
exam (1992-1996) and Framingham Offspring Studies (FOS) exam 5 (1991-1995). They 
analyzed data on 1081 NHW and 1656 MA from SAHS and 3224 white subjects from FOS, and 




of metabolic syndrome was 24% (by ATPIII and WHO criteria) in subjects from FOS; 23 and 
21% in NHW individuals and 31 and 30% in MA subjects from SAHS. The rates were highest 
among MA women 31% (ATP III) and 30% (WHO) and lowest among NHW women (21% ATP 
III). This study confirmed that metabolic syndrome was most prevalent among Mexican 
Americans. 
     Analysis of data on 3601 nationally representative non-institutionalized US populatin aged 
20 years or older from National Health and Nutrition Examination Survey 1999-2002 confirmed 
that Mexican American men and women (according to IDF criteria) have the hig st age 
adjusted prevalence of metabolic syndrome, 50.6% and 46.2%; respectively. The prevalence was 
lowest among White men and women (41.9% and 34.4%) and African American men and 
women (27.1% and 34.4%) (3). 
  
Diabetes in Hispanics 
     Diabetes is one of the most common chronic diseases worldwide. It affects nearly 200 million 
people (about 5 percent of the total adult population). In USA an estimated 20.8 million people 
(7% of the population) have diabetes and about 30% are unaware of the diagnosis (7, 181). 
Diabetes disproportionately affects Hispanics in the United States. According to National 
Institute of Health, National Diabetes Education Program, about 2.5 million or 9.5% of Hispanic 
or Latino Americans aged 20 years or older have been diagnosed with diabetes. Mexican 
Americans adults are 2 times more likely than non-Hispanic white adults to be diagnosed with 
diabetes by a physician. In 2002, Hispanics were 1.5 times as likely to start treatment for end-
stage renal disease related to diabetes, when compared to non-Hispanic white men and in 2003 
Hispanics were 1.5 times as likely as non-Hispanic Whites to die from diabetes (182, 183). 




fasting glucose in U.S. adults confirmed the information on the existence of health disparitie  
among minorities. They analyzed data on 4761 adults from NHANES 1999-2002. The age and 
sex adjusted prevalence of diagnosed diabetes was 10.4% among Mexican Americans and 5.2% 
in NHW (184). 
     According to Institute of Medicine (IOM), clear health care disparities exist when comparing 
diabetes care between White population and Minority groups (185). Recently, the diabet s car  
quality in Hispanics and non-Hispanic White adults was investigated by Mainous et al. They 
analyzed 2004 Behavioral Risk Factor Surveillance System (BRFSS) data on 18,510 NHW and 
2,078 Hispanics and observed less appropriate diabetes quality of care in Hispanics whe 
compared to NHW. Hispanics were also less likely to self monitor their disease. Ethnic 
disparities for receiving HbA1c tests and foot exams remained even after controlling for 
confounders including access to care, socioeconomic status and demographics (186).  
Multifaceted strategies for prevention and treatment of diabetes and improving diabetes care in 
Hispanics may help to eliminate disparities in this population.  
Cardiovascular Disease in Hispanics  
     Research has shown that Hispanics have a higher prevalence of CVD risk factor than non-
Hispanic Whites, including type 2 diabetes, obesity, lipid abnormalities and lower levels of 
physical activity, but lower cardiovascular disease and coronary heart disease mortality when 
compared to NHW individuals (187). In 2004, Hispanics were 10% less likely to have heart 
disease, as compared to NHWs. Less nonfatal CHD in Hispanics versus NHW has also been 
observed, especially among men and individuals with type 2 diabetes. However, findings from 
other studies like Corpus Christi Heart Project showed a higher incidence of myocardial 




Therefore, the actual cardiovascular disease pattern in this population is not well clear (166, 
187).  
     Swenson et al. in 2002 compared the all cause and CVD mortality in Hispanic and non 
Hispanic White participants of San Luis Valley Diabetes Study. Using medical records they 
investigated 310 deaths that occurred in 15 years follow-up from 1984-1998 among 1,862 
Hispanic and NHW individuals. The results revealed that among non-diabetics, there was no 
significant ethnic difference in risk for CVD or CHD death. Among individuals with type 2 
diabetes the risk of CVD and CHD were significantly lower in Hispanics than NHWs, 
particularly in men (187). Conversely, Hunt et al. in the analysis of San Antonio Heart Study 
have observed different results. They found excess risk of all-cause, CVD and CHD mortality is 
associated with being Mexican American. They present evidence against the “Hispanic 
Paradox”, which refers to the widely spread credence that Hispanics have lower all-cause and 
CVD mortality rates than NHW, despite their higher rates of diabetes and obesity, lower 
socioeconomic status and barriers to health care. The authors argue that such observations a e 
predominantly due to misclassification of ethnicity and causes of death for Hispanics (188, 189).  
 
Overweight and Obesity in Hispanics 
     Overweight and obesity elevate the risk of developing variety of chronic diseases, including 
cardiovascular disease, type 2 diabetes, stroke, hypertension, dyslipidemia, osteo rthri is, 
breathing problems, some cancers and depression (190, 191). The prevalence of overweight and 
obesity is increasing rapidly in United States among all ages, races, ethnicities, socioeconomic 
status and geographic regions. Based on data from National Health and Nutrition Exami ation 
Survey, the combined prevalence of overweight and obesity (BMI of 25 or higher) increased 




prevalence of obesity (BMI of 30 or higher) increased from 14.5% to 30.5% (nearly 110% raise). 
According to NHANES 2001-2002, racial disparities in weight exist among women, but not in 
men; among black women 68.6% are overweight or obese compared to 56.0% of white women 
and 54.5% of Hispanic women. Racial differences are more evident when obesity rat are 
compared; 41.5% of black women compared to 19.3% of white women and 26.2% of Hispanic 
women (7). In the analysis of NHANES 1999-2000, the prevalence of obesity was reported 29% 
and 40% in MA men and women, 27% and 30% in NHW men and women and 28% and 50% in 
NHB men and women, respectively (192). Although, poor diet and physical inactivity are major 
contributors to overweight and obesity, other factors such as aging, genetics, low socioeconomic 
status (low education, unemployment, poverty), acculturation and number of children for women 
have been related to overweight and obesity among some ethnic groups. Lack of health 
insurance, less access to health care services including services for prevention, treatment and 
management of overweight, obesity and their complications have been associated t Hispanics 
excess weight status (191, 193).  
Hypertension in Hispanics 
     Hypertension is a chief risk factor for heart disease and stroke, peripheral vascular nd end-
stage renal disease, and a strong predictor of premature death and adult disability. Although 
effective therapy has been available for more than 50 years, hypertension remai s as a major 
public health problem in United States (194). In 2004, the overall estimated prevalenc of 
hypertension was 72,000,000 and it was higher for females (39,000,000) than for males 
(33,000,000) (7). 
     According to AHA, hypertension is defined as untreated systolic pressure of 140 mm Hg or 




being told at least twice by a physician or other health professional that you have HBP. The pre-
hypertension is untreated systolic pressure of 120–139 mm Hg, or untreated diastolic pressure of 
80–89 mm Hg, and not being told on two occasions by a doctor or other health professionals that 
you have hypertension. An estimated 37.4 % of the U.S. population age 20 and older 
(41,900,000 men and 27,800,000 women) has pre-hypertension (7).  
     Several recent studies have reported that the prevalence of individuals with high blood 
pressure is increasing in the United States. The prevalence of hypertension increased from 25% 
in 1991-1994 to 31.3% in 1999-2000 (195-197). Analysis of NHANES 1999-2002 showed an 
age adjusted prevalence of 28.6% for hypertension (198), some part of these inconsistencie  may 
be related to redefining the cutoffs and criteria in defining high blood pressure (199). 
     In United Stated, ethnic/racial disparities in hypertension prevalence, awareness, treatment 
and control exist. Hypertension is more common in African Americans than in Whites, and 
Mexican Americans have the lowest prevalence when compared with Whites and African 
Americans. The lowest awareness, treatment and control rates of high blood pressure is also exist 
among Mexican Americans (195, 197).  Consistent with these findings, analysis of 
NHANES1999-2002 data demonstrate that the age-adjusted prevalence of hypertension was 
40.5% among NHB, 27.4% among NHW, and 25.1% in Mexican Americans. Among individuals 
with hypertension 70.3% of NHB, 62.9% of NHW and 49.8% of Mexican Americans were 
aware of their condition. The age-adjusted proportion who received antihypertensive medication 
was 55.4% among NHB, 48.6% among NHW and 34.9% among Mexican Americans. Only 29% 
of U.S. adults with hypertension had controlled blood pressure levels (<140/90 mm Hg). The 
proportion with controlled blood pressure was comparable in NHB and NHW (29%) but 




     Eliminating racial/ethnic disparities in hypertension awareness, prevention and control is an 
important public health issue and one of the Healthy People 2010 goals (200). Effective 
interventions are needed to prevent hypertension and /or improve blood pressure diagnosis and 
control in all populations, particularly among African Americans and Mexican Americans.  
Dyslipidemia in Hispanics  
     Among adults 20 years and older, the 2004 estimated prevalence of high LDL cholesterol 
(LDLc >130 mg/dL) was 79,300,000 (40,800,000 males; 38,600,000 females). The mean level of 
LDLc for American adults, age 20 and older, is 123 mg/dL, which is close to the borderline high 
level. According to AHA classification, levels of 130-159 mg/dL are considered borderline high; 
levels of 160-189 mg/dL are classified as high and LDLc >190mg/dL is considered v y high 
(7). Analysis of NHANES data 1999-2002 found, among NHW, the mean LDLc level was 126 
mg/dL for men and 121 mg/dL for women. Among NHB, the mean LDLc was 121 mg/dL for 
both men and women. Among Mexican Americans, the mean LDLc level was 125 mg/dL in men 
and 117 mg/dL in women (7). In 2007, the trends in the prevalence, awareness, treatment and 
control of LDLc were investigated by Hyre et al. (201). They compared data from 6497 
participants of NHANES III conducted in 1988-1994 and 5626 participants of NHANES 1999-
2004. High LDLc was defined based on NECP ATP III criteria.  
     The age adjusted prevalence of high LDLc among U.S. adults was 26.6% in 1988-1994 and 
25.3% in 1999-2004 (P = 0.28). During the periods of 1988-1994 and 1999-2004, awareness was 
increased significantly from 39.2% to 63.0%, use of pharmacologic lipid lowering medications 
increased significantly from 11.7% to 40.8% and among individuals with high LDLc levels, 




lower LDLc control rates compared with NHW (17.2% and 16.5% vs. 26.9%, respectively; p = 
0.05 and p = 0.008). 
     In adults age 20 and older, the 2004 estimated prevalence of HDLc <40mg/dL was 
44,100,000 (31,700,000 males; 12,300,000 females). The mean level of HDLc for American 
adults age 20 and older is 51.3 mg/dL. Findings from NHANES 1999-2002 revealed that mean 
HDLc was 45.5 and 52.9 mg/dL among NHW men and women, 51.0 mg/dL and 57.3 mg/dL 
among NHB men and women and 45.0 and 52.9 mg/dL among MA men and women, 
respectively (7). In the analysis of NHANES III, Ford et al. observed the highest age adjusted 
prevalence of decreased HDLc levels in Mexican Americans (39.6%), followed by NHW(37.9%) 
and NHB (28.8%)(2).  
      According to NHANES 1999-2002, the mean adult triglyceride levels for NHW, NHB and 
Mexican Americans were 140, 99 and 144 mg/dL, respectively (202). Reports from NHANES III 
documented that Mexican Americans (37.7%), have the highest age adjusted prevalence of 
hypertriglyceridemia (TG >150 mg/dL), followed by NHW (31.1%) and NHB (17.7%)  
     The National Cholesterol Education Program advises to self monitor plasma lipid levels as a 
good motivator for improving the management of hypercholesterolemia. Clinical trials suggest 
that informing patients of their plasma lipid condition may help to improve lipid control and 
dietary habits (203). Comparing to other ethnicities, Hispanics tend to have lower knowledge of 
hyperlipidemia and its associations with CVD and lipid lowering therapy. Consiste t with these 
findings, Kaplan et al. observed the same trend in the patients’ knowledge on elevated plasma 
cholesterol and lipid lowering medications. Their study showed, Hispanic subjects, particularly 
non-English speaking speakers, were significantly less likely to know about CVD risks and its 




and /or improve hyperlipidemia control in all populations especially among African Americans, 
Mexican Americans and older people.  
Dietary Patterns and Lifestyle in Hispanics 
     Latinos are a highly diverse group with a great variety in dietary traditions and food 
preferences. Hispanics dietary patterns like in any other ethnic group, account for cumulative and 
interactive effects of nutrients in food and reflect the interactions of biology, fod availability, 
customs, beliefs, education and lifestyle of this population. Several studies have report d that 
acculturation among Hispanics is positively correlated with poorer dietary choices including low 
intake of fruits and vegetables and high consumption of discretionary fat and soft drinks with 
added sugar (193, 204 and 205).  
     Sharma et al. examined the adherence to the food guide pyramid recommendations among 5 
different ethnic groups including African Americans and Latinos who participa ed in Multiethnic 
Cohort Study in Hawaii and Los Angeles. Subjects were 45-75 years and completed a s lf 
administered quantitative food frequency questionnaire at baseline in 1993 and after 3 years of 
follow up in 1996. The results revealed the lowest adherence among African Americans, 
Hawaiians and Latinos and the highest among Japanese American females and white females. 
They also found that non-U.S. born Latinos consumed 0.96 and 1.25 more servings of fruits and 
vegetables, respectively than their U.S. born counterparts. The author concluded that birthpl ce 
as one of the main components of acculturation, has a remarkable influence on fruits and 
vegetables intake in Latinos (204, 206). Nuehouser et al. investigated the associations of dietary 
patterns and acculturation among Hispanic immigrants from Mexico to Washington Sta e. 
Dietary intake data on fat, fruit and vegetable intake were collected on 1,689 adults by using the 




dietary assessment instruments. After adjusting for age, gender and socioeconomic factors, 
Latinos with higher acculturation scores had a significantly lower intake of fruits and vegetables 
(4.69 vs. 5.10 servings per day) compared to their less acculturated counterparts. Highly 
acculturated Latinos had vaguely higher scores on the Fat Related Diet Hab t questionnaire. 
Adding fat to breads and potatoes was one of the early dietary changes through acculturation 
(207).  
     Findings on the fat intake and its association with acculturation are inconsistent among 
Hispanic subgroups. Some studies on Mexican Americans suggest that those born in Mexico or 
those with less acculturation, have lower dietary fat intake (208, 209) and other studies how the 
opposite results (210). The association between dietary fat intake and acculturation vary among 
Hispanics with different origins. Many studies have reported higher fat consumption in Puerto 
Ricans compared to other Latino groups (193, 211). 
    Findings on sugar consumption in Hispanics and its association with acculturation are more 
consistent.  Several studies have found a positive association between sugar intake and 
acculturation among this population. Himmelgreen et al. (212) investigated the association of 
food consumption and acculturation among 174 low income Puerto Rican women in 
Connecticut. Acculturation was measured by length of time living in U.S., language use and 
birthplace. They observed a significantly higher consumption of soft drinks and other artificial 
drinks such as sodas and fruit drinks in Puerto Rican women who lived longer in U.S. (P=0.048). 
Consistent with these findings, Bermudez et al. documented a higher frequency consumption of 
foods with simple sugar in older Hispanics who resided longer in USA (213). 
     According to American Heart Association report based on National Health Interview Survey 




engaged in at least some leisure-time physical activity. Adults with higher education (graduate 
degree) and income (four times the poverty level and more) were more likely to be engaged in 
any regular physical activity. Trend studies show the prevalence of engaging in a regular 
physical activity is increasing in United States, although racial/ethnic disparities persist (7). In 
2005 only NHW men (52.3%) and NHW women (49.6%) had reached the Healthy People 2010 
goal of 50% of adults engaging in a regular physical activity (214). Cultural ba riers, education 
and poverty are major risk factors for a sedentary lifestyle and increasing obesity in Hispanics 
(193). Some of these factors might be modifiable through acculturation process.  
     Abradio-Lanza et al. analyzed data from 1991 National Health interview Survey, to examin  
the health behavior (including smoking, alcohol use, leisure-time physical activity and BMI) and 
acculturation hypotheses among Latinos. Acculturation was assessed by nativit status and 
length of stay in the U.S. After adjusting for age, education and income, acculturation w s 
positively associated with higher likelihood of recent exercise performance (215).  
     Using data from NHANES III, Crespo et al. (216) investigated the association between 
acculturation (as measured by language preferences at home, birth place and number of years 
lived in the U.S.) and leisure-time physical activity among Mexican American adults. Mexican 
American women had a higher age adjusted prevalence of physical inactivity than men. In both 
men and women, inactivity was lower among those who spoke mostly English than among those 
who spoke Spanish or both English and Spanish.  Inactivity patterns were less likely to b  seen in 
subjects who were born in U.S. and those who lived longer in the country. In a recent study 
Slattery et al. examined the associations between physical activity and language acculturation 
(using Spanish or English written and oral fluency) and their effect on obesity. The  analyzed 




Hispanics and non-Hispanic whites. The majority of women (25% Latinos vs. 35% whites, p< 
0.01) were not engaged in leisure-time physical activity at least 5 times per week for a minimum 
of 30 minutes. Variation in activity patterns (type and intensity) were noticed among Latino and 
non-Latino women. Latino women reported more housework, dependent care giving, dancing 
and work activity. Differences in activity patterns were observed by the level of acculturation. 
Latino women with low, intermediate and high levels of acculturation met 13.6%, 26.2% and 
28.4% of the leisure-time physical activity recommendations (217). According to CDC,
implementing culturally appropriate, community based physical activity interventions including 
walking clubs, free exercise classes and other culturally relevant activi ies can help to increase 
leisure-time physical activity in this population and other minority groups.  
     Cigarette smoking is the leading cause of preventable death in the United States, resulting in 
approximately 438,000 deaths annually. According to CDC in 2005, the direct medical and 
productivity lost associated with smoking was $167 billion (7). Reports from 2006 National 
Health Interview Survey (NHIS) revealed that around 20.8% of U.S. adults are current cigarette 
smokers (218). The prevalence of current cigarette smoking varies significantly by gender, 
education, income and population subgroups. It is higher among men (23.9%) than women 
(18.0%), among subjects with 9-11 years of education (35.4%) than those with more than 16 
years of education (6.6%) and among adults living below poverty levels (30.6%) than those at or 
above poverty level (20.4%). The prevalence is significantly lower in Hispanics (15.2%) than 
non-Hispanic blacks (23%) and non-Hispanic whites (21.9%).     
     Recently Bethel and Schenker reviewed published articles on acculturation and smoking 
patterns in Hispanic men and women in the United States (1985-2003). They found a gender-




was observed just in women but not among men. The authors concluded increasing cigarette
smoking in women could be related to the customs and practices’ influence of the dominant 
population (219).  
 
Elevated CRP in Hispanics 
     Reports on inflammatory markers distribution comparing different ethnic groups are far nd 
few.  Lin et al. (147) analyzed NHANES 1999-2002 to investigate the prevalence of metabolic 
syndrome and inflammation markers among White, Black and Mexican American adults ged 40 
years or older with and without diabetes. Among diabetes, the highest prevalence of elevated 
CRP was noticed among Blacks (24.5%), followed by Whites (17.7%) and Mexican Americans 
(17.3%). These differences were not statistically significant. Comparing CRP distribution among 
non-diabetes individuals showed, Blacks have substantially higher prevalence (17.4%) of 
elevated CRP than Mexican Americans (11.4%) and Whites (9.7%). More research is needed to 




Chapter 2: Methods 
 
Survey Description and Sample Design 
     The National Health and Nutrition Examination Surveys (NHANES) are a series of national 
studies that the National Center for Health Statistics, Center for Disease Control and Prevention 
(CDC) has been conducting since 1966 to assess the health and nutritional status of the U.S. 
population. 
     In the past (from 1971 to 1994), the NHANES were conducted on a periodic basis and the 
data were released as single, multiyear data sets. For example, NHANES III was conducted 
1988-1994 and can be analyzed as one, 6-year survey. In 1999, the survey became a continuous 
program that has a changing focus on different health and nutritional measurements to meet 
emerging public health issues. NHANES data are now released in two year cycles. Every year, 
the survey examines a nationally representative sample of about 5000 individuals. Participants 
are interviewed in their homes to obtain demographic, socioeconomic, dietary and health related 
information. Medical examinations, physiological measurements and laboratory tests are 
administered in mobile examination centers (MEC) by highly trained medical staff. Informed 
consent is obtained from all participants, and the institutional review board of the National 
Center for Health Statistics has approved the protocol. 
     The NHANES surveys use complex, stratified, multi-stage, clustered sampling of civilian, 
non-institutionalized U.S. population. A detailed description of design, procedures to selec the 
sample and content of each survey can be obtained from NHANES Analytic and Reporting 
Guidelines (220).  
     The sample design and weighting methodology for NHANES 1999-2006 is very similar to 




1. Selection of Primary Sampling Units (PSUs), which are generally single counties; 
sometimes small counties are combined to meet a minimum population size.  
 
2. Selection of Segments within PSUs; segment is a block or group of blocks containing a 
cluster of households. 
 
3. Selection of households within segments. 
 
4. Selection of one or more participants within households. 
 
A total of 15 PSUs was visited in 12 months period. For NHANES 1999-2000, there were 
12,160 individuals selected for the sample, 9,965 of those were interviewed (81.9 %) and 9,282 
(76.3 %) were examined in the MEC. For NHANES 2001-2002, there were 13,156 individuals 
selected for the sample, 11,039 of those were interviewed (83.9 %), and 10,477 (79.6 %) were 
examined in the MEC. For NHANES 2003-2004, there were 12,761 individuals selected for the 
sample, 10,122 of those were interviewed (79.3 %) and 9,643 (75.6 %) were examined in the 
MEC. The NHANES 2005-2006 contains data for 10,348 individuals of all ages (220, 221). 
 
 
Data Preparation and Use of Sample Weights 
 
     The continuous NHANES 1999-2006 data files from National Center for Health Statistics 
website is available for public use and will serve as the source of data for this study (222-225). 
These NHANES files consist of four separate data files including Demographic, Examination, 
Laboratory and Questionnaire. The multi-level data collection, information on specimen 
collection and processing and instructions on quality control systems are discussed in the 
Laboratory Procedures Manual of the NHANES 1999-2006 (226). All interview, laboratory, nd 
examination data are sent to NCHS for final processing.  
     Since the data sets for NHANES 1999-2006 are in a SAS format, data preparation (sorting, 




version 9.1 (SAS Institute Inc, Cary, NC). Identification number or sequence was used to sort the 
subjects and merge variables from different data files into one data set for each NHANES cycle 
and combine the cycles to form the final data set. 
     The appropriate sample weights, stratum variable (SDMVSTRA) and primary sampling unit 
(PSU) variable (SDMVPSU) were included in all analyses to account for the complex survey 
design, unequal probabilities of selection, non-response and over-sampling of selected 
population subgroups. By weighting the sample data, we produced estimates of statistics hat 
would have been obtained if the entire sampling population (for NHANES the entire sampling 
population is the United States) had been surveyed. The continuous NHANES 1999-2006 has 
over-sampled low income people, adolescents 10-12 years, elderly 60+ years, African mericans 
and Mexican Americans. The sample weight used in this study is calculated based on the 
recommendation from the National Center for Health Statistics and is the appropriate sample 
weight when data from combined cycles are analyzed (220, 228). 
Statistical Software 
     According to NHANES 2005-2006 Analytic and Reporting Guidelines, “software for survey 
data, such as SUDAAN or software that has specific survey procedures, such asSTATA and 
SAS, can be used to estimate sampling errors by the Taylor series (linearization) method” (220). 
Therefore, data preparation was performed using the Statistical Analysis Software (SAS) version 
9.1 (SAS Institute Inc, Cary, NC). SAS Callable SUDAAN (Software for the Statistical Analysis 
of Correlated Data) version 10.0 (Research Triangle Institute, Research Triangle Park, NC) was 
used to estimate descriptive and inferential statistics of interest and the associated variances. 
SUDAAN has the capability to analyze data from stratified, cluster or multistage sample designs 







     This study analyzed data on 3265 Mexican American adults aged 20-80 years who 
participated in the National Health and Nutrition Examination Survey (NHANES) 1999-2006. 
Subjects who were fasted less than 8 hours before venipuncture, pregnant and lactatingwome  
and participants with type 1 diabetes mellitus were excluded from the analysis. The study was 
approved by the Institutional Review Board at the University of Maryland. 
 
Variables of Interest 
 
The variables of interest are grouped together and placed into one of the following categories: 
Socio-demographic, Anthropometric, Biochemical and Clinical variables. 
     Socio-demographic variables including age, gender, marital status, language spoken at 
home, smoking, drinking alcohol, physical activity, income and education levels were assessed 
using the Sample Person and Family Demographic questionnaires (227).  
     Marital status was divided into two categories as married including living as married, and 
unmarried including being widowed, divorced, separated, never married or living with a partner. 
     Language spoken at home was classified into five categories as only Spanish, more Spanish 
than English, both equally, more English than Spanish and only English. 
     Cigarette smoking was categorized as never smoked (if they had smoked <100 cigarettes in 
their lifetime), former smoker (≥100 lifetime cigarettes, not currently smoking), and current 
smoker (≥100 lifetime cigarettes, currently smoking) (154). 
     Alcohol intake levels were determined from number and frequency of alcoholic beverag s 




alcoholic drinks consumed per month was then calculated and divided into 4 categories: <1, 1 to 
4, 5 to 7 and >7 drinks per month (147, 154).  
     Physical activity was defined based on frequency and duration of moderate or vigor us 
intensity leisure time activities and moderate tasks around the home or yard. Totl minutes per 
week spent performing these activities were computed and divided into 3 categories: 0 
min/week, < 150 and ≥150 min/week of moderate or vigorous physical activity (154, 230 and 
231). 
     Income status was defined based on Poverty Income Ratio (PIR) and divided into three levels 
(<1.85, 1.85-3.50 and >3.50) to represent low, middle and high income level, respectively (232). 
Poverty Income Ratio (PIR), the ratio of family income to poverty threshold, is an income 
criterion that varies by family size and composition. The U.S. Census Bureau uses PIR to define 
poverty status. PIR is also used as an eligibility criterion for participaton in federal and state 
assistance programs and as an index of relative socioeconomic status in National Health and 
Nutritional Examination Surveys. PIR values less than 1.00 are below the official poverty 
threshold while PIR values of 1.00 or greater indicate income above the poverty level (229).  
     Education was measured as the highest grade completed or the highest degree rec iv d by the 
respondent and was further categorized to less than high school, high school diploma and more 
than high school.  
     Anthropometric variables including weight, height, BMI and waist circumference (WC) 
were determined using Examination data files. Detailed information on descriptions of the 
NHANES protocol, survey equipment and quality control procedures can be obtained from 




     The participant’s weight was measured on a Toledo digital scalewith subjects wearing light 
clothing (underwear, disposable paper gowns and foam slippers). Weight was measured in 
pounds and was converted to kilograms in the automated system. Height was measured barefoot 
with a fixed stadiometer with a vertical backboard and a movable headboard. Subjects should 
move or remove hair ornaments, jewelry, buns and braids from the top of the head in order to 
measure stature properly. Body Mass Index (BMI) was calculated by dividing weight by squared 
height (Kg/m2) and categorized as; underweight (BMI<18.5), normal (18.5≤ BMI <25), 
overweight (25≤ BMI <30), obese (BMI ≥ 30). Waist circumference was measured with a steel 
measuring tape at the high point of the iliac crest in a horizontal plane at minimal respiration to 
the nearest 0.1 cm. 
     The following biochemical variables were included in the analysis: triglyceride (TG), total 
cholesterol (TC), HDL cholesterol (HDLc), LDL cholesterol (LDLc), fasting plasma glucose 
(FPG) and C-reactive protein (CRP). Detailed description on laboratory methods is available on 
NHANES website in the Laboratory Procedures Manual (234). Serum triglyceride (TG) 
concentration was measured enzymatically after hydrolyzing to glycerol. Serum total cholesterol 
(TC) was also measured enzymatically after hydrolyzing cholesteryl esters to free cholesterol 
and fatty acids. HDL cholesterol concentration was measured on a Roche HitachiAn lyzer after 
the precipitation of other lipoproteins with a heparin-manganese chloride mixture. Low Density 
Lipoprotein cholesterol (LDLC) was calculated according to Friedewald formula:  [LDLc] = 
[TC] – [HDLc] – [TG/5]. All the values in formula are expressed in mg/dl. This calculation is 
only valid for triglyceride less than 400 mg/dl. Fasting plasma glucose concntration was 
measured using an enzymatic reaction (enzyme hexokinase method) by the Diabetic Diagnostic 




morning examination session. C - reactive protein (CRP) was quantified by particle-enhanced 
assay (latex enhanced nephelometry). Particle-enhanced assays are based on the reaction 
between a soluble analyte and the corresponding antigen or antibody bound to polystyrene 
particles. 
     In this study, blood pressure, medication use, presence of inflammation, family histor of 
diabetes or stroke, menopausal status and estrogen use in women were categorized as clinical 
variables. Blood pressure was determined in mobile examination center using mercury 
sphygmomanometer in a sitting position after 5 minutes rest. Up to four blood pressure r adings 
were obtained. Participants who had three or four blood pressure readings, the averag of the last 
two measurements were used in the analysis. Those who had two blood pressure readings, the 
last measurement and participants who only had one reading, that measurement was co sidered 
as their blood pressure value. Information on blood pressure measurement procedures may b  
obtained from Physician Examination Procedures Manual (235, 236). Information on medication 
use including prescribed medicine for high blood pressure and hypercholesterolemia, lipid 
lowering statin medications, nonsteroidal anti-inflammatory and estrogen containing medications 
was obtained from questionnaire files (225, 237-239). 
     Chronic inflammation was determined if participant has been diagnosed with arthritis (240). 
Family history of diabetes, stroke/hypertension and angina were defined bas  on the presence of 
diabetes, stroke/hypertension and angina in biological relatives. Information on family history of 
hypertension/stroke was only available for 1999-2004 NHANES (240). Postmenopausal sttus 






Metabolic Syndrome risk factors 
     Metabolic syndrome risk factors were defined based on International Diabetes Fed ration 
criteria. According to this definition, subjects have metabolic syndrome if they have central 
obesity plus any two of the following factors: 1) Elevated triglycerides level: ≥ 150 mg/dl or 
specific treatment for this lipid abnormality; 2) Reduced high density lipoprotein cholesterol 
(HDLc) level: < 40 mg/dl in men and < 50 mg/dl in women or specific treatment for this lipid 
abnormality; 3) Elevated blood pressure: systolic blood pressure ≥ 130 or diastolic blood 
pressure ≥ 85 mmHg or treatment of previously diagnosed hypertension; 4) Elevated fasting 
plasma glucose:  ≥ 100 mg/dl or previously diagnosed type 2 diabetes and a combination of two 
or more of these risk factors (9). 
Assessment of Covariates 
     The information on covariates and potential confounders such as age (y), BMI (Kg/m2), 
marital status (married, unmarried), language spoken at home (only Spanish, more Spanish than 
English, both equally, more English than Spanish and only English), smoking habit (current, 
former and never), drinking alcohol, physical activity, economic status, education (< high school, 
high school diploma or general equivalency diploma and > high school), menopausal status (yes 
or no), current estrogen use (yes or no), medication use (yes or no), presence of arthritis (yes or 
no) and family history of diabetes (yes or no), family history of angina (yes or no) and family 
history of stroke (yes or no) were included in the analysis.   
Statistical Analysis 
     Descriptive statistics was applied for all variables, including mean and standard error of the 
mean (SEM) for continuous variables and relative frequencies for categorical variables. 




and frequencies of categorical variables in male and female subjects, respectiv ly. The estimates 
were considered unstable if the relative standard error for means or frequencies were greater than 
30%.  
     The distribution of all continuous variables including waist circumference, height, weight, 
BMI, fasting plasma glucose, triglycerides, HDL and LDL cholesterol, systolic and diastolic 
blood pressure and CRP were examined graphically to check for normality. Since CRP values 
were not normally distributed, the log transformed CRP were used in all analyses. The results 
were back transformed and reported as geometric mean of CRP. Multicollinearity among 
independent variables and also between confounders was tested in regression model by checking 
variance inflation factor (VIF). Any variable with VIF greater than 4 was excluded from the 
model (no variable with VIF greater than 4 was detected). We also checked for outliers by 
plotting predicted and observed standardized residuals. The outliers at the 0.01 level 
(standardized residuals > 2.58) were removed from the analysis. 
     The appropriate sample weights, stratum variable (SDMVSTRA) and primary sampling unit 
(PSU) variable (SDMVPSU) were included in all analyses to account for the complex survey 
design, unequal probabilities of selection, non-response and over-sampling of selected 
population subgroups (228).   
     Receiver Operating Characteristic (ROC) curve analysis was used to determine the 
appropriate gender specific waist circumference cutoffs that predict the pres nce of two or more 
risk factors of metabolic syndrome including, hypertriglyceridemia, hyperglycemia, hypertension 
and low HDL cholesterol. Using logistic regression analysis and plotting sensitivity vs. 1-
specificity, we investigated how accurately waist circumference (continuous predictor) could 




perfect predictor will have a point on ROC curve with 100% sensitivity and 100% specificity. 
The distance on ROC curve for WC values from perfect predictor was calculated as he square 
root of [(1-sensitivity) 2+ (1-specificity) 2]. The waist circumference value with the shortest 
distance on the ROC curve and maximum sensitivity and specificity was selected as the 
appropriate cutoff (53, 242). 
     Regression analysis was used to address the associations between WC and BMI with
triglycerides, fasting plasma glucose, HDL cholesterol, systolic and diastolic blood pressure (all 
continuous variables), in each gender after adjusting for age, income, alcohol intake, physical 
activity and the levels of education, smoking, marital status, language spoken at home, family 
history of diabetes, angina and stroke and menopausal status for women. Logistic re ression was 
used to estimate the odds ratios (ORs) of developing metabolic syndrome components 
(hypertriglyceridemia, hyperglycemia, hypertension and low HDL cholesterol) according to 
quartiles of waist circumference after controlling for potential confounders including age, 
income, alcohol intake, physical activity and the levels of education, smoking, marital status, 
language spoken at home, family history of diabetes, angina and stroke. The reference point was 
set at 25 percentile for waist circumference. 
     Regression analysis was used to address the associations between log transformed CRP with 
triglycerides, fasting plasma glucose, HDL cholesterol, systolic and diastolic blood pressure (all 
continuous variables), in each gender after adjusting for age, income, alcohol intake, physical 
activity and the levels of education, smoking, marital status, language spoken at home, chr nic 
inflammation, family history of diabetes, angina and stroke, medication use, menopausal status 
and estrogen use in women. Logistic regression was used to estimate the odds rati s (ORs) of 




hyperglycemia, hypertension and low HDL cholesterol) according to quartiles of CRP after 
controlling for potential confounders mentioned above. The reference point was set at 25 
percentile for CRP. 
     Data preparation (sorting, appending, merging and recoding) and ROC curve analysis were 
performed using Statistical Analysis Software (SAS) version 9.1 (SAS Institute Inc, Cary, NC). 
SUDAAN (Software for the Statistical Analysis of Correlated Data) version 9.0 (Research 
Triangle Institute, Research Triangle Park, NC) was used for all other analyses. Statistical 




Chapter 3: Appropriate Waist Circumference Cutoff Values for the 
Diagnosis of Metabolic Syndrome in Mexican American Adults 
ABSTRACT 
Background:  Metabolic syndrome increases the risk of cardiovascular disease and diabetes. 
The International Diabetes Federation (IDF) recently proposed new criteria for the diagnosis of 
metabolic syndrome, which requires the presence of central obesity as measured by ethnic 
specific waist circumference (WC) cutoff values. Currently, no specific WC thresholds for 
diagnosis of central obesity in Hispanics are available.  
Objective: The objectives were to determine the appropriate gender specific WC thresholds for 
diagnosis of central obesity in Mexican American adults and to estimate the prevalence of 
metabolic syndrome using IDF definition with and without the modified WC in this population.  
Design: Data from 3265 Mexican American adults aged 20-80 years who participated in the 
National Health and Nutrition Examination Survey 1999-2006 were used. The prevalenc of 
metabolic syndrome was compared using IDF criteria with and without the modified waist 
circumference.  
Results: Receiver operating characteristic curve analysis suggested that yielding at least 80% 
sensitivity, the WC value of 90 cm in both genders was more appropriate in predicting the 
presence of two or more metabolic syndrome risk factors in this population. Based on this cutoff, 
there was 34% reduction in the prevalence of central obesity in women (82.5% to 54.2%). The 
age adjusted prevalence of metabolic syndrome decreased from 58.4 to 48.2%. The metabolic 
syndrome was more common among Mexican American men than women (55.8% in men versus 




Conclusion: Our findings provided a practical guidance in the assessment and screening of 
central obesity and metabolic syndrome in Mexican Americans.  






     Metabolic syndrome, the clustering of metabolic risk factors including cetral obesity, insulin 
resistance, atherogenic dyslipidemia, hyperglycemia and hypertension is associated with 
increased risk of cardiovascular disease (CVD) and type 2 diabetes mellitus (1). This syndrome 
is one of the major medical and public health problems in the United States and worldwide (3-6). 
An estimated 47 million U.S. residents have metabolic syndrome and the age adjusted 
prevalence of syndrome is 23.7 percent (2, 7).  
     In the effort of introducing the metabolic syndrome into clinical practice and identifying 
individuals with this condition, several sets of criteria have been proposed by different 
organizations. World Health Organization (WHO), the European Group for the Study of Insulin
Resistance (EGIR), the American Association of Clinical Endocrinologists (AACE) and the 
National Cholesterol Education Program- Adult Treatment Panel III (NECP ATP III) have 
suggested some of the most accepted definitions (8-12). All of these definitions agree on the key 
elements of the metabolic syndrome including obesity, insulin resistance, hypertension and 
dyslipidemia; however they provide different criteria and cut points to define this cluster. The 
existence of several definitions was the main reason for proposing single unifying criteria by the 
International Diabetes Federation (IDF) in 2005, as a simple diagnostic tool for use in clinical 
practice and research worldwide. The IDF definition requires the presence of central obesity for 
diagnosis of metabolic syndrome. Central obesity is most easily measured by waist 
circumference (WC) with gender-ethnic specific thresholds (8). The current recommendations 
for defining central obesity in MAs (waist circumference ≥ 90 cm in men and ≥ 80 cm in 
women) are based on data from South Asia population and may not correctly estimate the 




adiposity and visceral fat accumulation (13-15). Studies on Asians have shown that for a given 
BMI or waist circumference, Asians had higher percentage of body fat when compared to 
Caucasians (16-18).  Findings from prospective study of 110 Hispanic and non-Hispanic white 
women revealed higher levels of adiposity and lower fat free mass in trunk region in Hispanic 
women (19).  
      Previous studies have shown a disproportionately high prevalence of metabolic syndrome, 
diabetes and CVD in Hispanics compared to non-Hispanic whites. Metabolic syndrome is more 
prevalent among Mexican Americans (MA) than non-Hispanic whites (31.9% vs. 23.8%). 
Hispanics are twice as likely to have diabetes as non-Hispanic whites of similar age. The 
prevalence of CVD is also high in this population and is comparable to non-Hispanic whites (7). 
Recently Ford et al. (2) reported that metabolic syndrome risk factors are very frequent in MA 
men and women. Obesity is epidemic among this population and abdominal obesity is present in 
nearly 46% of Mexican Americans. They also have a high incidence of other components of 
metabolic syndrome including: hypertriglyceridemia (37.7%), low levels of HDL cholesterol 
(39.6%), hypertension or being treated for blood pressure (36.6%) and hyperglycemia or tak ng 
medication for diabetes (20%). Considering the high incidence of metabolic syndrome, diabetes 
and CVD in the Hispanic population, there is an urgent medical, ethical and economical need to 
identify individuals with syndrome early, so that lifestyle interventions and treatment may 
prevent or delay the development of diabetes and/or CVD in this population.  
     In this study we investigated the appropriate waist circumference cutoffvalues for diagnosis 
of central obesity in Mexican American adults. We also compared the prevalence of metabolic 
syndrome based on IDF definition with and without the modified waist circumference in the 




SUBJECTS and METHODS 
Study population 
     This study analyzed data on 3265 Mexican American adults aged 20-80 years who 
participated in the National Health and Nutrition Examination Survey (NHANES) 1999-2006. 
The survey used complex, multi-stage, stratified, clustered sampling to access the health and 
nutritional status of the civilian, non-institutionalized U.S. population.  Participants were 
interviewed in their homes to obtain demographic, socioeconomic, dietary and health related 
information and were asked to attend the mobile examination center (MEC) to undergo medical 
examinations and laboratory tests. Detailed information on study design and sampleelection 
may be found elsewhere (20). Subjects who were fasted less than 8 hours before venipuncture, 
pregnant and lactating women and participants with type 1 diabetes mellitus were excluded from 
the analysis. The study was approved by the Institutional Review Board at the University of 
Maryland. 
Metabolic risk factors 
     Metabolic syndrome was defined based on IDF criteria. According to this definition, subjects 
have metabolic syndrome if they have central obesity plus any two of the following factors: 1) 
Elevated triglycerides level: ≥ 150 mg/dl or specific treatment for this lipid abnormality; 2) 
Reduced high density lipoprotein cholesterol (HDLc) level: < 40 mg/dl in men and < 50 mg/dl in 
women or specific treatment for this lipid abnormality; 3) Elevated blood pressure: systolic 
blood pressure ≥ 130 or diastolic blood pressure ≥ 85 mmHg or treatment of previously 
diagnosed hypertension; 4) Elevated fasting plasma glucose:  ≥ 100 mg/dl or previously 
diagnosed type 2 diabetes (8). 
     The IDF emphasizes the use of gender-ethnic specific thresholds for waist circumference 




Middle East (Arab) men, the specified cut point is WC ≥94 cm; for South Asian, Chinese, 
Japanese and ethnic South and Central American men, WC ≥90 cm; and in Women WC ≥80 cm 
is defined as central obesity(21).  In this analysis, the cut off values of 90 and 80 cm were used 
as original cutoffs to define central obesity in Mexican American men and women, respectively.  
     Waist circumference was measured with a steel measuring tape at the high point of the iliac 
crest in a horizontal plane at minimal respiration to the nearest 0.1 cm (22). Serum triglyceride 
(TG) concentration was measured enzymatically after hydrolyzing to glycerol. Serum total 
cholesterol (TC) was also measured enzymatically after hydrolyzing cholesteryl esters to free 
cholesterol and fatty acids. HDL cholesterol concentration was measured on a Roche Hitachi 
Analyzer after the precipitation of other lipoproteins with a heparin-manganese chloride mixture. 
Hypercholesterolemia was defined as TC ≥ 200 mg/dl or using cholesterol lowering medications.  
Low Density Lipoprotein cholesterol (LDLC) was calculated according to Friedewald formula:  
[LDLc] = [TC] – [HDLc] – [TG/5]. Fasting plasma glucose concentration was measured using 
an enzymatic reaction (enzyme hexokinase method) by the Diabetic Diagnostc Laboratory at the 
University of Missouri. C - reactive protein (CRP) was quantified by particle-enhanced assay 
(latex enhanced nephelometry). Detailed description of laboratory methods is available on 
NHANES website in the Laboratory Procedures Manual (23).  Blood pressure was determined in 
mobile examination center using mercury sphygmomanometer in a sitting position after 5 
minutes rest. Up to four blood pressure readings were obtained. Participants who had t ree or 
four blood pressure readings, the average of the last two measurements were used in the analysis. 
Those who had two blood pressure readings, the last measurement and participants who only had 




     Information on age, Body Mass Index (BMI), education and income levels, smoking and 
drinking habits, physical activity, marital status, language spoken at home, family history of 
diabetes, angina and stroke were also included in the analysis. BMI was calculated from weight 
and height values and classified according to standard definitions (26) as; underweight 
(BMI<18.5 kg/m2), normal weight (BMI=18.5-24.9 kg/m2), overweight (BMI= 25.0-29.9 kg/m2) 
and obesity (BMI ≥ 30 kg/m2). Education was measured as the highest grade completed or the 
highest degree received by the respondent and was further categorized to less than high school, 
high school diploma and more than high school. Income status was defined based on Poverty 
Income Ratio (PIR) and divided into three levels (<1.85, 1.85-3.50 and >3.50) to represent low, 
middle and high income level, respectively (27). Cigarette smoking was categorized as never 
smoked (if they had smoked <100 cigarettes in their lifetime), former smoker (≥100 lifetime 
cigarettes, not currently smoking), and current smoker (≥100 lifetime cigarettes, currently 
smoking). Alcohol intake levels were determined from number and frequency of alcoholic 
beverages consumed such as liquor, beer, wine and wine coolers in the past 30 days. The total 
number of alcoholic drinks consumed per month was then calculated and divided into 4 
categories: <1, 1 to 4, 5 to 7 and >7 drinks per month (28, 29). Physical activity categories were 
defined based on frequency and duration of moderate or vigorous intensity leisure time activiti s 
and moderate tasks around the home or yard. Total minutes per week spent performing these 
activities were computed and divided into 3 categories: 0 min/week, < 150 and ≥150 min/week 
of moderate or vigorous physical activity (28, 30 and 31). Marital status was classified into two 
categories as married including living as married, and unmarried including being widowed, 
divorced, separated, never married or living with a partner. Language spoken at home was 




English than Spanish and only English. Family history of diabetes, angina and 
stroke/hypertension were defined based on the presence of diabetes, angina and 
stroke/hypertension in biological relatives. Information on family history of hypertension/stroke 
was only available for 1999-2004 NHANES (32). Postmenopausal status was determin d if there 
had been complete menses cession ≥12 month (33). 
 
Statistical analysis 
     Descriptive statistics were applied for all variables, including mean and standard error of the 
mean (SEM) for continuous variables and relative frequencies for categorical variables. 
SUDAAN’s t-test and Chi square test were applied to compare the means of continuous variables 
and frequencies of categorical variables in male and female subjects, respectiv ly. The estimates 
were considered unstable if the relative standard error for means or frequencies were greater than 
30%. The appropriate sample weights, stratum variable (SDMVSTRA) and primary sampling 
unit (PSU) variable (SDMVPSU) were included in all analyses to account for the complex 
survey design, unequal probabilities of selection, non-response and over-sampling of selected 
population subgroups (34). Receiver Operating Characteristic (ROC) curve analysis was used to 
determine the appropriate gender specific waist circumference cutoffs that predict the presence 
of two or more risk factors of metabolic syndrome including, hypertriglyceridemia, 
hyperglycemia, hypertension and low HDL cholesterol. The distance on ROC curve for WC 
values was calculated by as the square root of [(1-sensitivity) 2+ (1-specificity) 2]. The waist 
circumference value with the shortest distance on the ROC curve and maximum sensitivity and 




predicted and observed standardized residuals. The outliers at the 0.01 level (standardized 
residuals > 2.58) were removed from the analysis.  
     Data preparation (sorting, appending, merging and recoding) and ROC curve analysis were 
performed using Statistical Analysis Software (SAS) version 9.1 (SAS Institute Inc, Cary, NC). 
SAS callable SUDAAN (Software for the Statistical Analysis of Crrelated Data) version 9.0 
(Research Triangle Institute, Research Triangle Park, NC) was used for all other analyses. 
Statistical significance was set at P <0.05 for both t-test and χ2 test.  
Results 
     The basic characteristics of the study population and the prevalence of metabolic risk factors 
are summarized in Table 3.1.The mean age was 37.1 ± 0.4 years for men and 39.5 ± 0.6 years 
for women (P =0.0001). Men were significantly taller and heavier and had larger WC than 
women. Significant differences in triglyceride, total cholesterol, LDL and HDL cholesterol, 
systolic and diastolic blood pressure and CRP values were found between genders. Family 
history of diabetes mellitus, angina and hypertension/stroke were more prevalent in women (P 
=0.0001). All metabolic risk factors were found to be significantly different between men and 
women. Generally, men were more likely to be married, speak Spanish at home, be current 
smokers, less educated and drink more alcohol as compared to women. Except for the middle 
income category, there were no significant differences in the values of income and physical 
activity in men and women (Table 3.2). 
     According to the IDF definition, the overall age adjusted prevalence of metabolic syndrome 
was 58.4% (55.8% in men and 64.8% in women, P =0.06).  Metabolic syndrome was 
significantly more prevalent in women in the 1st and 2nd quartile of waist circumference, 




than 3 mg/l and no moderate or vigorous physical activity. Current smokers and women who had 
less than one drink per month also were found to have higher prevalence of the metabolic 
syndrome (P <0.05 for all). However the metabolic syndrome was significantly higher in men 
with family history of angina and men who had more than 7 drinks per month (P =0.002 and P 
=0.05, respectively). There was a significant increase in the prevalence of metabolic syndrome 
across the levels of waist circumference and C-reactive protein (P for trend <0.001 for both). In 
addition, subjects with hypertension, reduced HDL cholesterol, hypertriglyceridemia and 
hyperglycemia had higher prevalence of metabolic syndrome compared to those who did not 
have these metabolic abnormalities (P =0.0001 for all). Metabolic syndrome was also more 
prevalent in participants who reported having family history of angina or stroke than those who 
did not have the family history of angina or stroke (P <0.05 for both). Former smokers had 
higher prevalence of metabolic syndrome compared to never smokers (P <0.01). However, the 
prevalence did not vary by family history of diabetes, drinking and physical activity s atus 
(Table 3.3). 
     The prevalence of having metabolic abnormalities including hypertriglyceridemia, 
hyperglycemia, hypertension, reduced HDL cholesterol or central obesity is presented in Figure 
3.1. Overall 89% of the population had one or more metabolic abnormality. Mexican American 
women were more likely to have one or more metabolic abnormalities than men (92% vs. 87%, 
P =0.001). There were no significant differences in prevalence of two or more or three or more 
metabolic abnormalities among genders. 
     According to ROC curve analysis, the optimal waist circumference cutoff values with 
maximum sensitivity and specificity for predicting the presence of two or more metabolic risk 




men and women (Figure 3.2). The sensitivity and specificity of this cutoff were 66.7% and 
60.4% in both genders, respectively (Table 3.4). Since IDF criteria requires the presence of 
central obesity for the diagnosis of metabolic syndrome, we justified to choose a cutoff point that 
obtains at least 80% sensitivity even if it causes a significant decreas  in specificity. Therefore, 
the appropriate waist circumference to predict two or more metabolic risk factors in Mexican 
Americans with 80% sensitivity was 90 cm in men and women, with a corresponding specificity 
of 45.6% in men and 45.8% in women. After applying the modified waist circumference of 90 
cm, we noticed 34% reduction in the prevalence of central obesity in women (82.5% to 54.2%). 
In addition, the prevalence of central obesity was significantly lower among women compared to 
men (54.2% vs. 69.8%, P =0.0001). The age adjusted prevalence of metabolic syndrome in 
women also decreased from 64.8% to 37.8%. With the original cutoff value of 80 cm, the 
syndrome was more prevalent in women (64.8% vs. 55.8%), while the reverse pattern was 
observed with the modified cutoff value of 90 cm and more men had metabolic syndrome 
(55.8% vs. 37.8%, P =0.0003) compared to women (Table 3.5).  
Discussion 
     Our findings suggest that waist circumference of 90 cm for both men and women is more
appropriate in predicting the presence of two or more metabolic risk factors and defining central 
obesity in Mexican American adults aged 20-80 years old. The WC value of 90 cm in men is 
smaller than the recommended obesity cutoff for Americans (102 cm) and Europeans (94 cm) 
and has been recommended by the joint World Health Organization (WHO)/ International 
Association for the Study of Obesity (IASO)/ International Obesity Task Force (IOTF) 
committee for defining central obesity in Asian populations (8, 37 and 38). The same cutoff 




Japanese and South and Central American men (21). Our finding on WC cut point in men is 
consistent with the results from previous studies who examined the appropriate waist 
circumference for central obesity in different ethnic populations. Analysis of data on 4723 
Chinese, Malay and Asian-Indian men and women from 1998 Singapore National Health Survey 
suggested that WC of 90 cm was more appropriate in defining central obesity in this population 
(14). Using data from Korean Health and Nutritional Examination Survey 1998, Lee and 
colleagues also reported that the WC of 90 cm was more appropriate in determining metabolic 
syndrome risk factors in Korean men (39).   
     We suggest that the WC value of 90 cm would be more appropriate for defining central 
obesity and predicting the presence of two or more metabolic risk factors in Mexican American 
women. This value differs from recommended thresholds for American (88 cm) and European 
(80 cm) women by 2 and 10 cm, respectively. There is a 10 cm gap between our cutoff for 
women (90 cm) and the value recommended by WHO/ IASO/IOTF committee for defining 
obesity in Asian women and the IDF proposed cutoff for central obesity and defining metabolic 
syndrome in South Asian, Chinese and South and Central American women (80 cm). However, 
this finding follows the results from a previous study on determining the optimal waist 
circumference cutoff for obesity in Japanese women (40). Consistent with this finding, Zhu et al. 
(33) in analyzing data from NHANES III found the WC value of 94 cm as a more appropriate 
threshold in determining cardiovascular disease risk factors in Mexican American women.  
     According to the waist circumference cutoff identified in the present study, the prevalence of 
central obesity among men and women were 69.8% and 54.2%, respectively. In contrast to our 
result, Ford et al. (2) in the analysis of data from NHANES III reported that central obesity as 




American women compared to men (62.7% vs. 30.6%). Using data from NHANES 1999-2000, 
Flegal and colleagues also found obesity to be more prevalent among Mexican American women 
than men (40% vs. 29%). However, they used different criteria in defining the central obesity 
(41). 
     Based on IDF definition and the waist circumference cutoff proposed by our study the age 
adjusted prevalence of metabolic syndrome was 55.8% and 37.8% in men and women, 
respectively. Consistent with this finding, Ford and colleagues in the study of data from 
NHANES 1999-2002, reported higher prevalence of metabolic syndrome among men than 
women (50.6% vs. 46.2%)(3). Some of the differences in the estimates of prevalence in these 
studies might be explained by applying different waist circumference cutoff points in defining 
central obesity and metabolic syndrome. In the Ford et al. study they used the thresolds of 90 
cm for men and 80 cm for women (3). However, in both studies the IDF criteria for metabolic 
syndrome were used. 
     Our results are not applicable to all Hispanics as only Mexican Americans were over sampled 
in NHANES and the small number of ‘other Hispanics’ in data set were not sufficient to be 
analyzed as a separate group. To our knowledge, this is the first study to investigate the 
appropriate waist circumference cutoff for diagnosis of central obesity and metabolic syndrome 
in Mexican Americans adults, using 8 years of continuous NHANES 1999-2006 data. The 
findings of the present study are derived from a representative sample of Mexican American 
adults in the United States and are applicable to this population.      
     In summary, our results indicated that the appropriate waist circumference to predict two or 
more metabolic risk factors in Mexican Americans is 90 cm in men and women. According to 




American men than women. The current study will contribute not only to the understanding of 
the importance of appropriate assessment of central obesity in screening mtabolic syndrome but 
also to provide practical guidance in identifying individuals with metabolic syndrome and taking 
proper procedures to prevent or delay the development of diabetes and /or cardiovascular 
disease.  
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Appendices1   
Table 3.1. Basic characteristics and metabolic risk indicators among Mexican American adults aged 20-80 
years, NHANES 1999-2006* 
* HDL, high density lipoprotein; LDL, low density lipoprotein; SBP, systolic blood pressure; DBP, diastolic blood 
pressure. The means of all continuous variables and frequencies of all categorical variables were compared in men 
and women using SUDAAN’s t test and χ 2 test, respectively. Statistical significance was set at P <0.05. 
† Values are means (SEM) for continuous variables and percentages (SEM) for categorical variables. 
‡Metabolic risk factors were defined according to IDF definition (21): elevated triglyceride, ≥ 150 mg/dl or specific 
treatment for hypertriglyceridemia; reduced HDL cholesterol, < 40 mg/dl for men and <50 mg/dl for women or 
specific treatment for this lipid abnormality; elevated blood pressure, systolic blood pressure ≥ 130 mmHg, diastolic 
blood pressure ≥85 mmHg or treatment for previously diagnosed hypertension; elevated fasting plasma glucose ≥ 100 
mg/dl or previously diagnosed type 2 diabetes; central obesity, waist circumference ≥ 90 cm for men and ≥ 80 cm for 
women. 
 § Significant difference between men and women. ¶ Unstable estimates. 
Variables 
 Total  Men  Women 
  n Mean or % (SEM)†   n Mean or % (SEM)   n Mean or % (SEM) 
Age (y) 3265 38.07 (0.52) 1794 37.08 (0.46) 1471 39.50 (0.67)§ 
Height (cm) 3223 165.05 (0.18) 1780 169.97 (0.25) 1443 157.88 (0.23)§ 
Weight (kg) 3203 76.56 (0.41) 1764 80.69 (0.59) 1439 70.57 (0.58)§ 
Body mass index (kg/m2) 
< 18.5 (%) 
≥ 18.5 to < 25 (%) 
≥ 25 to < 30 (%) 































Waist Circumference (cm) 3139 95.02 (0.41) 1726 96.69 (0.55) 1413 92.62 (0.58)§ 
Fasting plasma glucose (mg/dl) 1421 104.16 (1.07) 789 104.91 (1.31) 632 103.08 (1.77) 
Total cholesterol (mg/dl) 1407 196.37 (1.47) 783 199.90 (1.91) 624 191.22 (2.00)§ 
HDL cholesterol (mg/dl) 1408 49.20 (0.48) 784 46.33 (0.50) 624 53.39 (0.69)§ 
LDL cholesterol (mg/dl) 1343 117.82 (1.21) 737 123.03 (1.54) 606 110.51 (1.57)§ 
Triglycerides (mg/dl) 1407 155.65 (6.12) 783 166.00 (8.70) 624 140.55 (6.86)§ 
SBP (mmHg) 2939 119.20 (0.51) 1631 120.56 (0.60) 1308 117.19 (0.66)§ 
DBP (mmHg) 2939 70.33 (0.31) 1631 70.97 (0.41) 1308 69.38 (0.37)§ 
C-reactive protein (mg/l) 1415 2.65 (0.10) 786 2.17 (0.10) 629 3.35 (0.13)§ 






















Metabolic risk factors (%)‡ 
Elevated triglyceride 
Reduced HDL cholesterol 
Elevated blood pressure 

























































Table 3.2. Socio-economic and behavioral characteristics of the study population, NHANES 1999-2006 
Characteristics 
Total Men Women 
   n    % (SEM)    n    % (SEM)    n   % (SEM) 
Education (y) 
     <12  
      12  


























     Married 



















Language spoken at home  
     Only Spanish  
     Spanish > English  
     Spanish = English  
     English > Spanish  






































     Low  
     Middle 

























Smoking status  
     Never 
     Former 

























Alcohol intake (drink/mon) 
     <1  
     1-4  
     5-7  































Physical activity (min/wk) 
     0  
     ≤ 150  

























§ The frequencies of categorical variables were compared in men and women using SUDAAN’s χ 2 test. Statistical 




Table 3.3. The age adjusted prevalence of the metabolic syndrome among Mexican American adults 
aged 20-80 years by cardiovascular risk factors, NHANES 1999-2006* 
Characteristics 
Total Men Women 
   n   % (SEM)    n   % (SEM)   n   % (SEM) 
Waist circumference (cm) 
    <86  
    86-94.1  
    94.2-103.2  





























100.0 (0.00)   
100.0 (0.00) 
Hypertension  
     Yes 
















     Yes 













Reduced HDL cholesterol 
     Yes 














     Yes 
















     Yes 













Family history of diabetes 
     Yes 

















63.65 (3.97)  
66.98 (5.29)¶ 
Family history of angina 
     Yes 



















Family history of stroke or 
hypertension 
     Yes 



















Physical activity (min/wk) 
     0  
     ≤ 150  

























C-reactive protein (mg/l) 
     <1  
     1-3  



























Smoking status  
    Never 
    Former 


























     <1  
     1-4  
     5-7  














































*The age adjusted prevalence of metabolic syndrome was compared across the levels of cardiovascular 
risk factors and between men and women using SUDAAN’s χ 2 test. Metabolic syndrome was defined 




†Hypercholesterolemia was defined as total cholesterol ≥ 200 mg/dl or using cholesterol lowering 
medications.  
‡P for trend <0.0001; §P <0.01(comparing the levels of cardiovascular risk factors); ¶ P <0.01(comparing 
men and women) 
 
 
Table 3.4. Sensitivity, specificity and distance in the receiving 
operating characteristic (ROC) curve for waist circumference 















*  Metabolic risk factors were defined according to IDF definition 
(21): elevated triglyceride, ≥ 150 mg/dl or specific treatment for 
hypertriglyceridemia; reduced HDL cholesterol, < 40 mg/dl for men 
and <50 mg/dl for women or specific treatment for this lipid 
abnormality; elevated blood pressure, systolic blood pressure ≥ 130
mmHg, diastolic blood pressure ≥85 mmHg or treatment for 
previously diagnosed hypertension; elevated fasting plasma glucose 
≥ 100 mg/dl or previously diagnosed type 2 diabetes.  
  
 
                                            2 or more metabolic risk factors 
 




















































































Table 3.5. The age adjusted prevalence of the metabolic syndrome and central obesityamong Mexican 
American adults aged 20-80 years by gender, NHANES 1999-2006*  














% (SEM) % (SEM) % (SEM) % (SEM) % (SEM) % (SEM) 
IDF waist 
circumference‡ 58.4 (2.14) 55.8 (2.88) 64.8 (3.25) 0.06 75.0 (1.25) 69.8 (1.82) 82.5 (1.43) 0.0001 
Modified waist 
circumference§ 48.2 (1.91) 55.8 (2.88) 37.8 (3.03) 0.0003 63.4 (1.29) 69.8 (1.82) 54.2 (2.06) 0.0001 
*The age adjusted prevalence of metabolic syndrome and central obesity was compared in men and 
women using SUDAAN’s t test. Statistical significance was set at P <0.05. 
†Metabolic syndrome was defined according to IDF definition (21): elevated triglyceride, ≥ 150 mg/dl or 
specific treatment for hypertriglyceridemia; reduced HDL cholesterol, < 40 mg/dl for men and <50 mg/dl 
for women or specific treatment for this lipid abnormality; elevated blood pressu e, systolic blood pressure 
≥ 130 mmHg, diastolic blood pressure ≥85 mmHg or treatment for previously diagnosed hypertension; 
elevated fasting plasma glucose ≥ 100 mg/dl or previously diagnosed type 2 diabetes; central obesity, waist 
circumference ≥ 90 cm for men and ≥ 80 cm for women.  
‡Waist circumference ≥ 90 cm for men and ≥ 80 cm for women.  







Figure 3.1.  Prevalence of the metabolic abnormalities among Mexican American 
adults aged 20-80 years, NHANES 1999-2006. * Significant difference in prevalence 







Figure 3.2. The ROC curves for waist circumference to predict the presence of two or more 
metabolic syndrome risk factors based on IDF definition in men and women.    , waist 
circumference cutoff with maximum sensitivity and specificity.     , waist circumference cutoff 




Chapter 4: Abdominal Adiposity, Overall Obesity and Metabolic 
Syndrome in Mexican American Adults: Findings from the National 
Health and Nutrition Examination Surveys 1999-2006  
 
ABSTRACT 
Background:  Abdominal adiposity is one of the main features in identifying individuals with 
metabolic syndrome (MetS). The association between abdominal adiposity and the components 
of MetS is not well studied in Mexican Americans.  
Objective: The objective of this study was to examine the association between abdominal 
adiposity and overall obesity with the elements of MetS in Mexican American adults. We also 
compared the odds ratios of developing MetS risk factors according to quartiles of WC in this 
population. 
Design: We analyzed data from 3265 Mexican American adults aged 20-80 years who 
participated in the NHANES 1999-2006. Regression analysis was used to determine the 
relationship between WC and BMI with fasting plasma glucose, systolic and diastolic blood 
pressure and lipid abnormalities in each gender after adjusting for relevant confounders. Logistic 
regression was used to estimate the odds ratios of developing MetS components according to 
quartiles of waist circumference. 
Results: All correlation coefficient of WC and BMI with the components of MetS were 
significant among men (P <0.05). In both genders, higher WC was significantly associated with 
higher risk of having metabolic abnormalities. Compared with individuals in the lowest WC 
quartile, those in the highest quartile were 9 times more likely (95% CI: 5.00, 14.96) to have 2 or 




Conclusion: WC had a stronger association with almost all of the MetS risk factors than BMI in 
Mexican American men and women. Higher levels of WC were associated with an increased risk 
of metabolic abnormalities. 
KEY WORDS   Metabolic syndrome, waist circumference, body mass index, obesity, 





     Metabolic syndrome, the clustering of metabolic risk factors including central obesity, insulin 
resistance, atherogenic dyslipidemia, hyperglycemia and hypertension is associated with 
increased risk of cardiovascular disease (CVD) and type 2 diabetes mellitus (1). This syndrome 
is one of the major medical and public health problems in the United States and worldwide and s 
prevalent among all ethnic groups in USA (2-8). According to International Diabetes Federation 
(IDF) criteria, Mexican Americans have the highest age adjusted prevalence of metabolic 
syndrome (around 50%) (3). 
     Central obesity is one of the main features in identifying individuals with metabolic 
syndrome. The hypotheses relating central obesity to metabolic syndrome focus on the hormonal 
role of adipose tissue (particularly visceral adipose tissue) and secretion of adipokines 
(cytokines) and other bioactive substances such as free fatty acids. Adipose tissue actively 
secretes large number of hormones and adipokines including leptin, adiponectin, tumor necrosis
factor α (TNFα), interleukin 6 (IL-6), monocyte chemotactic protein 1, inducible nitric oxide 
synthase (iNOS), plasminogen activator inhibitor 1 (PAI-1) and resistin. These adipokines have 
autocrine, paracrine and endocrine actions for controlling different metabolic functions (9-11). 
The expanding adipose tissue also discharges high levels of FFA into the portal and systemic 
circulation (12-14); this may result in accumulation of lipid in areas other than adipose tissue or 
ectopic fat storage syndrome. In muscles and liver, increased FFA is associated with insulin 
resistance (15, 16) and dyslipidemia (17).  
     The association between obesity and the components of metabolic syndrome has been 
investigated by anthropometric measurements such as body mass index (BMI), waist to hip ratio 




obesity and provides estimation of total body fat with no further information on the distribution 
of excess fat storage. Waist to hip ratio measures abdominal fat accumulation, and has less 
power in predicting health risk factors when compared to waist circumference. Waist 
circumference reflects the amount of abdominal adipose tissue storage as well as total fat mass, 
providing a measure of body fat distribution. It also complements BMI in predicting obesity 
related diseases and health risks (19-21). Several studies have shown that waist circumference is 
a better predictor of metabolic abnormalities and cardiovascular disease risk factors than BMI 
(21-23). 
     Little information is available on the association of abdominal adiposity, overall obesity and 
the components of metabolic syndrome in Mexican Americans (24). Most of the previous studie
have focused on non Hispanic Whites or non representative population samples (18-21). 
Therefore the aim of the present study was to examine the association between abdominal 
adiposity, measured by waist circumference and overall obesity, measured by body mass index 
with the components of metabolic syndrome including, triglyceride, blood pressure, fasting 
plasma glucose and HDL cholesterol in Mexican American adults using National Health and 
Nutrition Examination Survey (NHANES) 1999-2006 data. We also investigated the odds for 
developing metabolic syndrome risk factors according to quartiles of waist circumference in this 
population. 
SUBJECTS and METHODS 
Study population 
     This study analyzed data on 3265 Mexican American adults aged 20-80 years who 
participated in the National Health and Nutrition Examination Survey (NHANES) 1999-2006. 




nutritional status of the civilian, non-institutionalized U.S. population.  Participants were 
interviewed in their homes to obtain demographic, socioeconomic, dietary and health related 
information and were asked to attend the mobile examination center (MEC) to undergo medical 
examinations and laboratory tests. Detailed information on study design and sample election 
may be found elsewhere (25). Subjects who were fasted less than 8 hours before venipuncture, 
pregnant and lactating women and participants with type 1 diabetes mellitus were excluded from 




     Body weight and height were measured to the nearest 0.1 kg and 0.1 cm, respectively, by 
using standardized equipment and proper procedures (26). Waist circumference was masured 
with a steel measuring tape at the high point of the iliac crest in a horizontal plane at minimal 
respiration to the nearest 0.1 cm. BMI was calculated from measured weight and eight and 
categorized as; underweight (BMI less than 18.5 Kg/m2), normal (BMI=18.5-24.9 Kg/m2), 
overweight (BMI=25-29.9 Kg/m2) and obese (BMI = 30 Kg/m2 and higher) (27).  
Metabolic risk factors 
     Metabolic syndrome was defined based on IDF criteria. According to this definition, subjects 
have metabolic syndrome if they have central obesity plus any two of the following factors: 1) 
Elevated triglycerides level: ≥ 150 mg/dl or specific treatment for this lipid abnormality; 2) 
Reduced high density lipoprotein cholesterol (HDLc) level: < 40 mg/dl in men and < 50 mg/dl in 
women or specific treatment for this lipid abnormality; 3) Elevated blood pressure: systolic 




diagnosed hypertension; 4) Elevated fasting plasma glucose:  ≥ 100 mg/dl or previously 
diagnosed type 2 diabetes (28). 
     The IDF emphasizes the use of gender-ethnic specific thresholds for waist circumference 
when measuring central obesity. For Europid, Sub-Saharan African, Eastern Mediterranean and 
Middle East (Arab) men, the specified cut point is WC ≥94 cm; for South Asian, Chinese, 
Japanese and ethnic South and Central American men, WC ≥90 cm; and in Women WC ≥80 cm 
is defined as central obesity (29).  In this analysis, the cut off values of 90 and 80 cm were used 
to define central obesity in Mexican American men and women, respectively.  
     Serum triglyceride (TG) concentration was measured enzymatically after hydrolyzing to 
glycerol. Serum total cholesterol (TC) was also measured enzymatically after hydrolyzing 
cholesteryl esters to free cholesterol and fatty acids. HDL cholesterol concentration was 
measured on a Roche Hitachi Analyzer after the precipitation of other lipoproteins with a 
heparin-manganese chloride mixture. Hypercholesterolemia was defined as TC ≥ 200 mg/dl or 
using cholesterol lowering medications.  Low Density Lipoprotein (LDL) cholesterol was 
calculated according to Friedewald formula:  [LDLc] = [TC] – [HDLc] – [TG/5]. Fasting plasma 
glucose concentration was measured using an enzymatic reaction (enzyme hexokinase method) 
by the Diabetic Diagnostic Laboratory at the University of Missouri. C-reactive protein (CRP) 
was quantified by particle-enhanced assay (latex enhanced nephelometry). D tailed description 
of laboratory methods is available on NHANES website in the Laboratory Procedures Manual 
(30).  Blood pressure was determined in mobile examination center using mercury 
sphygmomanometer in a sitting position after 5 minutes rest. Up to four blood pressure 
measurements were obtained. Participants who had three or four blood pressure readings, the 




pressure readings, the last measurement and participants who only had one reading, that 
measurement was considered as their blood pressure value (31, 32).  
  Confounding variables   
     Age, education, income, smoking and drinking habits, physical activity, marital status, 
language spoken at home, family history of diabetes, angina and stroke and menopausal status 
for women may be associated with development of metabolic syndrome. As potential 
confounders, these variables were included in regression models. Age was modeled as a 
continuous variable. Education was measured as the highest grade completed or the highest 
degree received by the respondent and was further categorized to less than high school, high 
school diploma and more than high school. Income was measured based on Poverty Income 
Ratio (PIR) and modeled as a continuous variable. For descriptive purposes, three PIR categories 
(<1.85, 1.85-3.50 and >3.50) were defined to represent low, middle and high income level, 
respectively (33). Cigarette smoking was categorized as never smoked (if thy had smoked <100 
cigarettes in their lifetime), former smoker (≥100 lifetime cigarettes, not currently smoking), and 
current smoker (≥100 lifetime cigarettes, currently smoking). Alcohol intake was determined 
from number and frequency of alcoholic beverages consumed such as liquor, beer, wine and 
wine coolers in the past 30 days. The total number of alcoholic drinks consumed per month was 
calculated and modeled as a continuous variable. The total alcohol intake was further divided 
into 4 categories: <1, 1 to 4, 5 to 7 and >7 drinks per month and applied in descriptive analysis 
(34, 35). Physical activity was defined based on frequency and duration of moderate or vigorous 
intensity leisure time activities and moderate tasks around the home or yard. Totl minutes per 
week spent performing these activities were computed and modeled as continuous variable. For 




vigorous physical activity were produced (34, 36 and 37). Marital status was classified into two 
categories as married including living as married, and unmarried including being widowed, 
divorced, separated, never married or living with a partner. Language spoken at home was 
divided into five categories as only Spanish, more Spanish than English, both equally, more 
English than Spanish and only English. Family history of diabetes, stroke/hypertension and 
angina were defined based on the presence of diabetes, stroke/hypertension and angin  in
biological relatives. Information on family history of hypertension/stroke was only available for 
1999-2004 NHANES (38). Postmenopausal status was determined if there had been complte 
menses cession ≥12 month (39). 
Statistical analysis 
     Descriptive statistics were applied for all variables, including mean and standard error of the 
mean (SEM) for continuous variables and relative frequencies for categorical variables. 
SUDAAN’s t-test and Chi square test were applied to compare the means of continuous variables 
and frequencies of categorical variables in male and female subjects, respectiv ly. The estimates 
were considered unstable if the relative standard error for means or frequencies were greater than 
30%. Regression analysis was used to address the associations between WC and BMI with
triglycerides, fasting plasma glucose, HDL cholesterol, systolic and diastolic blood pressure (all 
continuous variables), in each gender after adjusting for age, income, alcohol intake, physical 
activity and the levels of education, smoking, marital status, language spoken at home, family 
history of diabetes, angina and stroke and menopausal status for women. Logistic re ression was 
used to estimate the odds ratios (ORs) of developing metabolic syndrome components 
(hypertriglyceridemia, hyperglycemia, hypertension and low HDL cholesterol) according to 




income, alcohol intake, physical activity and the levels of education, smoking, marital status, 
language spoken at home, family history of diabetes, angina and stroke. The reference point was 
set at 25 percentile for waist circumference. Multicollinearity among independent variables and 
also between confounders was tested in regression model by checking variance infl tion factor 
(VIF). Any variable with VIF greater than 4 was excluded from the model (no variable with VIF 
greater than 4 was detected). We also checked for outliers by plotting predicted and observed 
standardized residuals. The outliers at the 0.01 level (standardized residuals > 2.58) were 
removed from the analysis.    
     Data preparation (sorting, appending, merging and recoding) was performed using Statistical 
Analysis Software (SAS) system version 9.2 (SAS Institute Inc, Cary, NC). SAS Callable 
SUDAAN (Software for the Statistical Analysis of Correlated Data) version 10.0 (Research 
Triangle Institute, Research Triangle Park, NC) was used for data anlyses. Statistical 
significance was set at 0.05 unless otherwise indicated. The appropriate sampl weights, stratum 
variable (SDMVSTRA) and primary sampling unit (PSU) variable (SDMVPSU) were included 
in all analyses to account for the complex survey design, unequal probabilities of selection, non-
response and over-sampling of selected population subgroups (40).  
Results 
     The basic characteristics of the study population and the prevalence of metabolic risk factors 
are summarized in Table 4.1.The mean age was 37.1 ± 0.4 years for men and 39.5 ± 0.6 years 
for women (P =0.0001). Men were significantly taller and heavier and had larger WC than 
women. Significant differences in triglyceride, total cholesterol, LDL and HDL cholesterol, 
systolic and diastolic blood pressure and CRP values were found between genders. Family 




=0.0001). All metabolic risk factors were found to be significantly different between men and 
women. Overall 89% of the population had one or more metabolic abnormality. Mexican 
American women were more likely to have one or more metabolic abnormalities than men 
(92.3% vs. 86.9%, P =0.001). There were no significant differences in prevalence of two or more 
or three or more metabolic abnormalities among genders. Based on IDF definition me abolic 
syndrome was prevalent in 58.4% of the population (55.8% among men and 64.8% among 
women, P =0.06) (data not shown). Table 4.2 presents the socio-economic and behavioral 
characteristics of the study population. Generally, men were more likely to be married, speak 
Spanish at home, be current smokers, less educated and drink more alcohol as compared to 
women. Except for the middle income category, there were no significant differences in the 
values of income and physical activity in men and women. 
     Correlation coefficients for WC and BMI with metabolic syndrome risk factors are shown in 
Table 4.3 WC and BMI were highly correlated in both men and women (r= 0.935, n=777 in men 
and r= 0.895, n=619 in women; P <0.0001 for both). All correlation coefficients of WC and BMI 
with the components of metabolic syndrome were significant among men (P <0.05). In women, 
WC and BMI were significantly correlated with HDL cholesterol. In both genders the correlation 
coefficients were stronger between WC and metabolic risk factors than those of BMI; however 
the reverse pattern was noticed in correlation between WC and BMI with HDL cholester  in 
women. 
     The odds ratios (ORs) and 95% confidence interval (CI) for one or more metabolic syndrome 
risk factors according to quartiles of waist circumference are presnt d in Table 4.4 The ORs of 
metabolic syndrome risk factors increased from 1st to 4th quartile of waist circumference (P for 




quartile had an OR of 4.18 (95% CI: 1.96, 8.93) for elevated triglyceride, 3.50 (95% CI: 1.69, 
7.26) for elevated blood pressure, 5.71 (95% CI: 3.24, 10.09) for reduced HDL cholesterol and 
2.34 (95% CI: 1.32, 4.14) for elevated fasting plasma glucose, respectively, after adjustment for 
relevant confounders (P < 0.001 for all). These subjects were also 9 times more likely (95% CI: 
5.00, 14.96) to have 2 or more metabolic risk factors when compared to the lowest WC quartile 
and after adjustment for the mentioned confounders (P <0.0001). 
Discussion 
     Our findings suggest that waist circumference had a stronger association with almost all of 
the metabolic syndrome risk factors than body mass index in Mexican American men and 
women. This finding is consistent with the results from previous studies in which WC showed 
greater association with cardiovascular disease and diabetes risk factors when compared to BMI 
in Hispanic and non Hispanic white populations (24, 41-43). Most recently, Wang et al. (41) 
compared the predictive power of WC, WHR and BMI in diagnosing type 2 diabetes mellitus in 
27270 men from Health Professionals Follow-Up Study and found WC to be a better predictor 
than BMI or WHR. This may be because waist circumference, a simple anthropometric easure, 
reflects the amount of abdominal adipose tissue storage and is considered as the best marker of 
abdominal visceral fat (44-46). Adipose tissue, particularly visceral adipose tissu , actively 
secretes large number of hormones and adipokines such as leptin, adiponectin, tumor necrosis 
factor α (TNFα), interleukin 6 (IL-6),  plasminogen activator inhibitor 1 (PAI-1), inducible nitric 
oxide synthase (iNOS), resistin and more. These adipokines have autocrine, paracrine nd 
endocrine actions for controlling different metabolic functions (9-11). The expanding a pose 




14); this may result in promoting insulin resistance and dyslipidemia in muscles and liver (15-
17).  
     We also observed that higher levels of waist circumference were associated with an increased 
risk of metabolic abnormalities including hypertension, hyperglycemia and lipid abnormalities. 
This association was independent of age, gender, education, income, language spoken at hom , 
marital status, lifestyle factors and family history of diabetes, angin  and stroke. Subjects in the 
highest quartile of waist circumference were 9 times more likely, even aft r controlling for 
confounders, to have two or more metabolic risk factors. This finding is consistent with the 
reports from previous studies where abdominally obese subjects had higher risk for devel ping 
metabolic syndrome, cardiovascular disease or type 2 diabetes mellitus (19, 39 and 44). Findings
from analyzing national surveys are also in agreement with our results. Park et al. in the analysis 
of NHANES III data observed higher odds ratios for developing metabolic syndrome in 
overweight and obese individuals (47).  
     Obesity is correlated with inflammatory responses, characterized by abnormal adipokines 
production and overproducing of some inflammatory markers (9, 11). Recent data indicate that 
obese adipose tissue is infiltrated by macrophages, which are responsible for the most part of the 
locally produced TNFα and large amounts of IL-6 and inducible nitric oxide synthase expression 
(48, 49). Adipose tissue TNFα increases adipocyte lipolysis and may increase insulin resistance 
by promoting the fatty acid release from adipose tissue into the portal and systemic circulation 
(15, 16). IL-6 also increases lipolysis and fat oxidation in humans (50) and raises plasma 
concentration of fibrinogen, PAI-1 and CRP (51). Overproduction of IL-6 by adipose tissue 




and hypertriglyceridemia, since visceral adipose tissue (VAT) is closely connected to liver by the 
portal venous system (52).    
     Our study has some limitations. The cross –sectional nature of the study would not allow us to 
establish causal relationships between metabolic syndrome risk factors and waist circumference. 
In addition, our results are not applicable to all Hispanics as only Mexican Americans were over 
sampled in NHANES and the small number of ‘other Hispanics’ in data set were not sufficient to 
be analyzed as a separate group.  
     To our knowledge, this is the first study to investigate the association between abdominal 
adiposity and overall obesity with the components of metabolic syndrome in Mexican American 
adults using 8 years of continuous NHANES 1999-2006 data. The findings of the present study 
are derived from a representative sample of Mexican American adults in the Unied States and 
are applicable to this population. 
     In summary, our findings indicated that waist circumference had a stronger association with 
almost all of the metabolic syndrome risk factors than body mass index in Mexican American 
men and women. We also observed that the risk of having metabolic abnormalities increases 
sharply in subjects with central obesity. This study not only helps to better understa the 
association between waist circumference and metabolic risk factors in Mexcan American adults 
but also emphasizes the importance of central obesity in increasing risk of having metabolic 
abnormalities. Multifaceted strategies for prevention, treatment and magement of overweight 
and obesity are required. Lifestyle modifications including nutritional education, weight control 
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Table 4.1. Basic characteristics and metabolic risk indicators among Mexican American adults aged 20-80 
years, NHANES 1999-2006* 
* HDL, high density lipoprotein; LDL, low density lipoprotein; SBP, systolic blood pressure; DBP, diastolic blood 
pressure. The means of all continuous variables and frequencies of all categorical variables were compared in men 
and women using SUDAAN’s t test and χ 2 test, respectively. Statistical significance was set at P <0.05. 
†Values are means (SEM) for continuous variables and percentages (SEM) for categorical variables. 
‡Metabolic risk factors were defined according to IDF definition (29): elevated triglyceride, ≥ 150 mg/dl or specific 
treatment for hypertriglyceridemia; reduced HDL cholesterol, < 40 mg/dl for men and <50 mg/dl for women or 
specific treatment for this lipid abnormality; elevated blood pressure, systolic blood pressure ≥ 130 mmHg, diastolic 
blood pressure ≥85 mmHg or treatment for previously diagnosed hypertension; elevated fasting plasma glucose ≥ 100 
mg/dl or previously diagnosed type 2 diabetes; central obesity, waist circumference ≥ 90 cm for men and ≥ 80 cm for 
women. 
 § Significant difference between men and women. ¶ Unstable estimates.  
Variables 
 Total  Men  Women 
  n Mean or % (SEM)†   n Mean or % (SEM)   n Mean or % (SEM) 
Age (y) 3265 38.07 (0.52) 1794 37.08 (0.46) 1471 39.50 (0.67)§ 
Height (cm) 3223 165.05 (0.18) 1780 169.97 (0.25) 1443 157.88 (0.23)§ 
Weight (kg) 3203 76.56 (0.41) 1764 80.69 (0.59) 1439 70.57 (0.58)§ 
Body mass index (kg/m2) 
< 18.5 (%) 
≥ 18.5 to < 25 (%) 
≥ 25 to < 30 (%) 































Waist Circumference (cm) 3139 95.02 (0.41) 1726 96.69 (0.55) 1413 92.62 (0.58)§ 
Fasting plasma glucose (mg/dl) 1421 104.16 (1.07) 789 104.91 (1.31) 632 103.08 (1.77) 
Total cholesterol (mg/dl) 1407 196.37 (1.47) 783 199.90 (1.91) 624 191.22 (2.00)§ 
HDL cholesterol (mg/dl) 1408 49.20 (0.48) 784 46.33 (0.50) 624 53.39 (0.69)§ 
LDL cholesterol (mg/dl) 1343 117.82 (1.21) 737 123.03 (1.54) 606 110.51 (1.57)§ 
Triglycerides (mg/dl) 1407 155.65 (6.12) 783 166.00 (8.70) 624 140.55 (6.86)§ 
SBP (mmHg) 2939 119.20 (0.51) 1631 120.56 (0.60) 1308 117.19 (0.66)§ 
DBP (mmHg) 2939 70.33 (0.31) 1631 70.97 (0.41) 1308 69.38 (0.37)§ 
C-reactive protein (mg/l) 1415 2.65 (0.10) 786 2.17 (0.10) 629 3.35 (0.13)§ 






















Metabolic risk factors (%) ‡ 
Elevated triglyceride 
Reduced HDL cholesterol 
Elevated blood pressure 

























































Table 4.2. Socio-economic and behavioral characteristics of the study population, NHANES 1999-2006* 
Characteristics 
Total Men Women 
   n    % (SEM)    n    % (SEM)    n   % (SEM) 
Education (y) 
     <12  
      12  


























     Married 



















Language spoken at home  
     Only Spanish  
     Spanish > English  
     Spanish = English  
     English > Spanish  






































     Low  
     Middle 

























Smoking status  
     Never 
     Former 

























Alcohol intake (drink/mon) 
     <1  
     1-4  
     5-7  































Physical activity (min/wk) 
     0  
     ≤ 150  

























*The frequencies of categorical variables were compared in men and women using SUDAAN’s χ 2 test. Statistical 
significance was set at P <0.05. 






Table 4.3. Correlation coefficients of waist circumference or body mass index with me abolic 
syndrome risk factors* 
 WC TG HDLc FPG SBP DBP 
Men 
Waist circumference 








































*  WC, waist circumference; TG, triglyceride; HDLc, high density lipoprotein cholesterol; SBP, 
systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose. SUDAAN’s 
regress procedure was used to determine the correlation coefficients of WC and BMI with metabolic 
risk factors after adjusting for age, income, alcohol intake, physical activity and levels of education, 
smoking, marital status, language spoken at home, family history of diabetes, angina and stroke and 
menopausal status in women.  
Except for the correlation coefficient of WC and BMI with TG, FPG, SBP and DBP in women (§), all 





Table 4.4. Odds ratios and 95% confidence interval for metabolic syndrome risk factors accding to 
quartiles of waist circumference in Mexican American adults* 
 
Components of  
metabolic syndrome 
Quartile of waist circumference 
P for 
trend Q1(<86.0 cm) Q2 (86.0-94.1 cm) Q3 (94.2-103.2 cm) Q4 (>103.2 cm) 
n = 276 n = 312 n = 403 n = 408 
Elevated triglyceride 1.00 2.80 (1.30-6.04)† 3.75 (1.88-7.51) 4.18 (1.96-8.93) 0.0005 
Elevated blood pressure 1.00 2.21 (1.23-3.96) 3.06 (1.65-5.69) 3.50 (1.69-7.26) 0.001 
Elevated fasting plasma 
glucose 
1.00 1.38 (0.73-2.60) 1.93 (0.93-4.01) 2.34 (1.32-4.14) 0.001 
Reduced HDL cholesterol 1.00 2.09 (1.16-3.76) 4.44 (2.55-7.73) 5.71 (3.24-10.09) <0.0001 
2 or more metabolic risk 
factors‡ 1.00 3.87 (2.08-7.20) 6.88 (3.80-11.47) 8.93 (5.00-14.96) <0.0001 
*Odds ratios of having metabolic risk factors were compared across the quartile of waist circumference (the lowest 
quartile as reference group). The logistic regression model was adjusted for age, income, alcohol intake, physical activity 
(all continuous variables) and the levels of gender, education, smoking, marital status and language spoken at home and 
family history of diabetes, angina and stroke. 
†All such values are adjusted OR (95% CI). 
‡Metabolic risk factors (excluding central obesity) were defined according to IDF definition (29): elevated triglyceride, ≥ 
150 mg/dl or specific treatment for hypertriglyceridemia; elevated blood pressure, systolic blood pressur  ≥ 130 mmHg, 
diastolic blood pressure ≥85 mmHg or treatment for previously diagnosed hypertension; elevated fasting plasma glucose 
≥ 100 mg/dl or previously diagnosed type 2 diabetes; r duced HDL cholesterol, < 40 mg/dl for men and <50 mg/dl for 






Chapter 5: Metabolic Syndrome and C - reactive protein Levels among 
Mexican American Adults: Findings from the National Health and 
Nutrition Examination Surveys, 1999-2006 
 
ABSTRACT 
Background:  Several studies have found associations between low grade inflammation and 
metabolic syndrome (MetS) risk factors, cardiovascular disease (CVD) and diabetes mellitus. 
Little information is available on C-reactive protein (CRP) distribution and its relation with MetS 
in Mexican Americans (MAs). 
Objective: The objective of this study was to investigate the association between CRP and MetS 
in MA adults. We also compared the odds ratios (ORs) of developing MetS or its components 
(central obesity, hypertriglyceridemia, hyperglycemia, hypertension and low HDL cholesterol) 
according to quartiles of CRP in this population. 
Design: Data from 3265 MA adults aged 20-80 years who participated in the National Health 
and Nutrition Examination Survey 1999-2006, were used. Regression analysis was used to 
address the associations between log transformed CRP with the components of MetS a ter 
adjusting for the relevant confounders. Logistic regression was used to estimat  the odds ratios 
of developing MetS according to quartile of CRP after controlling for potential confounders.  
Results: CRP concentrations were higher in subjects with MetS. Significant associations were 
observed between CRP and MetS components. Higher CRP concentrations were significantly 
associated with higher risk of having MetS. In multiple logistic regression analysis with age, 
gender, drinking, smoking, marital status, medication use, arthritis and all the components of 




Conclusion: MAs with MetS and low grade inflammation may be at higher risk for developing 
CVD and diabetes. Appropriate approaches for prevention, treatment and management of MetS 
and/or chronic inflammation are needed. 
 
KEY WORDS   Metabolic syndrome, Low grade inflammation, C-reactive protein, Central 






     Metabolic syndrome, the clustering of metabolic risk factors including cetral obesity, insulin 
resistance, atherogenic dyslipidemia, hyperglycemia and hypertension is associated with 
increased risk of cardiovascular disease (CVD) and type 2 diabetes mellitus (1). This syndrome 
is one of the major medical and public health problems in the United States and worldwide and s 
prevalent among all ethnic groups in USA (2-8). According to International Diabetes Federation 
(IDF) criteria, nearly 50% of Mexican Americans have metabolic syndrome (3). 
     A proinflammatory state is frequently present in patients with metabolic syndrome and is 
recognized by elevated inflammatory markers such as interleukin-1, interleukin-6, tumor 
necrosis factor-α, intercellular adhesion molecule-1, C- reactive protein (CRP) and elevated 
leukocyte count (9-11). CRP, an acute phase reactant produced by liver is the most studied 
biomarker of low grade inflammation and increases in response to infection, injury and chro ic 
inflammation. Physical activity, smoking, alcohol consumption, estrogen use, lipid lowering 
statin and anti-inflammatory medications have been documented to alter the CRP concentrations 
(11, 12). CRP distributions vary by gender and ethnicity (13-16). Previous studies have shown 
higher levels of CRP among women than men. Mexican American and Black individuals also 
have higher CRP concentrations when compared to Caucasians (17, 18). Several studies have 
found associations between higher levels of CRP and metabolic syndrome risk factors (19-21), 
cardiovascular disease (22-24) and diabetes mellitus (25-27). Little informati n is available on 
CRP distribution and its relation with metabolic syndrome in Mexican Americans. Most of the 
previous studies have focused on individual components of metabolic syndrome, non Hispanic 
Whites or non representative population samples (16, 19, 26 and 28). Therefore the aim of the 




syndrome in Mexican American adults using National Health and Nutrition Examination Survey 
(NHANES) 1999-2006 data. We also estimated the odds ratios for developing metabolic 
syndrome or its components (central obesity, hypertriglyceridemia, hypergl c mia, hypertension 
and low HDL cholesterol) according to quartiles of CRP in this population. 
SUBJECTS and METHODS 
Study population 
     This study analyzed data on 3265 Mexican American adults aged 20-80 years who 
participated in the National Health and Nutrition Examination Survey (NHANES) 1999-2006. 
The survey used complex, multi-stage, stratified, clustered sampling to access the health and 
nutritional status of the civilian, non-institutionalized U.S. population.  Participants were 
interviewed in their homes to obtain demographic, socioeconomic, dietary and health related 
information and were asked to attend the mobile examination center (MEC) to undergo medical 
examinations and laboratory tests. Detailed information on study design and sampleelection 
may be found elsewhere (29). Subjects who were fasted less than 8 hours before venipuncture, 
pregnant and lactating women and participants with type 1 diabetes mellitus or serum CRP level 
greater than 10 mg/L (indication of acute illness or injury) were excluded from the analysis. The 
study was approved by the Institutional Review Board at the University of Maryland. 
Survey methods 
     Metabolic syndrome was defined based on IDF criteria. According to this definition, subjects 
have metabolic syndrome if they have central obesity plus any two of the following factors: 1) 
Elevated triglycerides level: ≥ 150 mg/dl or specific treatment for this lipid abnormality; 2) 
Reduced high density lipoprotein cholesterol (HDLc) level: < 40 mg/dl in men and < 50 mg/dl in 




blood pressure ≥ 130 or diastolic blood pressure ≥ 85 mmHg or treatment of previously 
diagnosed hypertension; 4) Elevated fasting plasma glucose:  ≥ 100 mg/dl or previously 
diagnosed type 2 diabetes (30). The IDF emphasizes the use of gender-ethnic specific thresholds 
for waist circumference when measuring central obesity. For Europid, Sub-Saharan African, 
Eastern Mediterranean and Middle East (Arab) men, the specified cut point is WC ≥94 cm; for 
South Asian, Chinese, Japanese and ethnic South and Central American men, WC ≥90 cm; and 
in Women WC ≥80 cm is defined as central obesity (31).  In this analysis, the cut off values of 
90 and 80 cm were used to define central obesity in Mexican American men and women, 
respectively.  
     Body weight and height were measured to the nearest 0.1 kg and 0.1 cm, respectively, by 
using standardized equipment and proper procedures (32). Waist circumference was masured 
with a steel measuring tape at the high point of the iliac crest in a horizontal plae at minimal 
respiration to the nearest 0.1 cm. Body mass index (BMI) was calculated from measured weight 
and height and categorized as; underweight (BMI less than 18.5 Kg/m2), normal (BMI=18.5-24.9 
Kg/m2), overweight (BMI=25-29.9 Kg/m2) and obese (BMI = 30 Kg/m2 and higher) according to 
World Health Organization classification (33).  
     Serum triglyceride (TG) concentration was measured enzymatically after hydrolyzing to 
glycerol. Serum total cholesterol (TC) was also measured enzymatically after hydrolyzing 
cholesteryl esters to free cholesterol and fatty acids. HDL cholesterol concentration was 
measured on a Roche Hitachi Analyzer after the precipitation of other lipoproteins with a 
heparin-manganese chloride mixture. Hypercholesterolemia was defined as TC ≥ 200 mg/dl or 
using cholesterol lowering medications.  Low Density Lipoprotein (LDL) cholesterol was 




glucose concentration was measured using an enzymatic reaction (enzyme hexokinase method) 
by the Diabetic Diagnostic Laboratory at the University of Missouri. CRP was quantified by 
particle-enhanced assay (latex enhanced nephelometry) on a BN II nephelometer at the 
University of Washington Medical Center (Seattle, WA). Detailed description on laboratory 
methods is available on NHANES website in the Laboratory Procedures Manual (34).  Blood 
pressure was determined in mobile examination center using mercury sphygmomanometer in a 
sitting position after 5 minutes rest. Up to four blood pressure readings were obtained. 
Participants who had three or four blood pressure readings, the average of the last two 
measurements were used in the analysis. Those who had two blood pressure readings, the last 
measurement and participants who only had one reading, that measurement was considered a  
their blood pressure value (35, 36).  
  Confounding variables   
     Age, education, income, smoking and drinking habits, physical activity, marital status, 
language spoken at home, chronic inflammation, family history of diabetes, angina and stroke, 
lipid lowering statin and anti-inflammatory medications, estrogen containing medications and 
menopausal status in women may be associated with development of metabolic syndrome or 
alter the CRP concentrations (11, 28, 37 and 38). As potential confounders, these variables were 
included in regression models. Age was modeled as a continuous variable. Education was 
measured as the highest grade completed or the highest degree received by the respondent and 
was further categorized to less than high school, high school diploma and more than high school. 
Income was measured based on Poverty Income Ratio (PIR) and modeled as a continuous 
variable.  For descriptive purposes, three PIR categories (<1.85, 1.85-3.50 and >3.50) were 




categorized as never smoked (if they had smoked <100 cigarettes in their lifetime), former 
smoker (≥100 lifetime cigarettes, not currently smoking), and current smoker (≥100 lifetime 
cigarettes, currently smoking). Alcohol intake was determined from number and fequency of 
alcoholic beverages consumed such as liquor, beer, wine and wine coolers in the past 30 days. 
The total number of alcoholic drinks consumed per month was calculated and modeled as a 
continuous variable. The total alcohol intake was further divided into 4 categories: <1, 1 to 4, 5 
to 7 and >7 drinks per month and applied in descriptive analysis (40, 41). Physical activity was 
defined based on frequency and duration of moderate or vigorous intensity leisure time activiti s 
and moderate tasks around the home or yard. Total minutes per week spent performing these 
activities were computed and modeled as continuous variable. For descriptive purposes 3 
categories (0 min/week, < 150 and ≥150 min/week) of moderate or vigorous physical activity 
were produced (40, 42 and 43). Marital status was classified into two categories as married 
including living as married, and unmarried including being widowed, divorced, separatd, never 
married or living with a partner. Language spoken at home was divided into five categories as 
only Spanish, more Spanish than English, both equally, more English than Spanish and only 
English. Family history of diabetes, stroke/hypertension and angina were defin d based on the 
presence of diabetes, stroke/hypertension and angina in biological relatives. Information on 
family history of hypertension/stroke was only available for 1999-2004 NHANES (44). 
Postmenopausal status was determined if there had been complete menses cession ≥12 month 
(38). Information on over the counter and prescription medications that may alter CRP levels 
including lipid lowering statin medications, nonsteroidal anti-inflammatory medications and 




medication questionnaire (45-47). Chronic inflammation was determined if participan  has been 
diagnosed with arthritis (44).  
Statistical analysis 
     Descriptive statistics was applied for all variables, including mean and st ndard error of the 
mean (SEM) for continuous variables and relative frequencies for categorical variables. 
SUDAAN’s t-test and Chi square test were applied to compare the means of continuous variables 
and frequencies of categorical variables in male and female subjects, respectiv ly. The estimates 
were considered unstable if the relative standard error for means or frequencies were greater than 
30%. Since CRP values were not normally distributed, the log transformed CRP were used in all 
analyses. The results were back transformed and reported as geometric mean ofCRP. Regression 
analysis was used to address the associations between log transformed CRP with triglycerides, 
fasting plasma glucose, HDL cholesterol, systolic and diastolic blood pressure (all continuous 
variables), in each gender after adjusting for age, income, alcohol intake, physical activity and 
the levels of education, smoking, marital status, language spoken at home, chronic inflammation, 
family history of diabetes, angina and stroke, medication use, menopausal status and estrogen 
use in women. Logistic regression was used to estimate the odds ratios (ORs) of devel ping 
metabolic syndrome and its components (central obesity, hypertriglyceridemia, hyperglycemia, 
hypertension and low HDL cholesterol) according to quartiles of CRP after controlling for 
potential confounders mentioned above. The reference point was set at 25 percentile for CRP. 
Multicollinearity among independent variables and also between confounders was tested in 
regression model by checking variance inflation factor (VIF). Any variable with VIF greater than 




checked for outliers by plotting predicted and observed standardized residuals. The outliers at the 
0.01 level (standardized residuals > 2.58) were removed from the analysis.    
     Data preparation (sorting, appending, merging and recoding) was performed using Statistical 
Analysis Software (SAS) system version 9.2 (SAS Institute Inc, Cary, NC). SAS Callable 
SUDAAN (Software for the Statistical Analysis of Correlated Data) version 10.0 (Research 
Triangle Institute, Research Triangle Park, NC) was used for data anlyses. Statistical 
significance was set at 0.05. The appropriate sample weights, stratum variable (SDMVSTRA) 
and primary sampling unit (PSU) variable (SDMVPSU) were included in all an yses to account 
for the complex survey design, unequal probabilities of selection, non-response and over-
sampling of selected population subgroups (48).  
Results 
     The basic characteristics of the study population and the prevalence of metabolic risk factors 
are summarized in Table 5.1.The mean age was 37.1 ± 0.4 years for men and 39.5 ± 0.6 years 
for women (P =0.0001). Men were significantly taller and heavier and had larger WC than 
women. The geometric mean concentration of CRP was 2.65 mg/l for the whole population. 
Women had higher CRP concentrations compared to men (3.35 mg/l vs. 2.17 mg/l, P <0.01). In 
addition, the percentage of women with CRP concentrations greater than 3 mg/l was significantly 
higher than men (46.6% vs. 24.7%, P <0.0001). Significant differences in triglyceride, total 
cholesterol, LDL and HDL cholesterol, systolic and diastolic blood pressure values wer  found 
between genders. Family history of diabetes mellitus, angina and hypertension/stroke were more 
prevalent in women (P =0.0001). All metabolic risk factors were found to be significantly 
different between men and women. Overall 89% of the population had one or more metabolic 




abnormalities than men (92.3% vs. 86.9%, P =0.001). Based on IDF definition metabolic 
syndrome was prevalent in 58.4% of the population (55.8% among men and 64.8% among 
women, P =0.06) (data not shown). Compared to men the prevalence of arthritis and medication 
use was double in women (P =0.001). Table 5.2 presents the socio-economic and behavioral 
characteristics of the study population. Generally, men were more likely to be married, speak 
Spanish at home, be current smokers, less educated and drink more alcohol as compared to 
women. Except for the middle income category, there were no significant differences in the 
values of income and physical activity in men and women. 
     The geometric mean concentrations of CRP were significantly higher among subject  with 
metabolic syndrome than those who did not have metabolic syndrome (2.31 mg/l vs. 0.81 mg/l, 
P <0.01). Participants with central obesity, hypertriglyceridemia, hypertension and reduced HDL 
cholesterol also had higher levels of CRP concentrations than subjects without those conditions 
(P <0.01 for all). The age adjusted prevalence of elevated CRP was higher in subjects with 
metabolic syndrome than those without the syndrome (42.7% vs. 17.2%, P <0.01) (Table 5.3). 
The CRP levels increased gradually with increasing the numbers of metabolic syndrome 
components from 0.7 to 3.1 mg/l (Figure 5.1).  
     The age adjusted prevalence of metabolic syndrome increased from 26.9% to 81.6% as the 
CRP concentrations increased, P <0.0001 (Table 5.4). The increment pattern was observed in 
both genders across the CRP quartiles. Women in the highest CRP quartile had significantly 
higher prevalence of metabolic syndrome than men (87.8% vs. 75.2%, P <0.01). C-reactive 
protein was significantly associated with almost all the elements of metabolic syndrome (except 
for diastolic blood pressure). All correlation coefficients were stronger among women than men 




     The odds ratios (ORs) and 95% confidence interval (CI) for metabolic syndrome and its 
components according to quartiles of CRP are presented in Table 5.6 The ORs of metabolic 
syndrome or its components increased across the CRP quartiles. Compared with individuals in 
the lowest CRP quartile, those in the highest quartile had an OR of 2.11 (95% CI: 1.23, 3.61) for 
elevated triglyceride, 0.93 (95% CI: 0.51, 1.69) for elevated fasting plasma glucose, 6.91 (95% 
CI: 3.56, 11.40) for central obesity, 1.65 (95% CI: 0.72, 3.76) for hypertension and 2.88 (95% 
CI: 1.68, 4.94) for reduced HDL cholesterol, respectively, after adjustment for age, gender, 
alcohol intake, smoking (model 1), marital status, language spoken at home, medication use and 
arthritis (model 2). In order to decrease the number of variables in the logistic regression models, 
education, income and physical activity were dropped from the original model as th ir β 
coefficient was equal to zero and their effect was not significant. Individuals with highest CRP 
concentrations were 9.9 times more likely (95% CI: 4.53, 16.63) to have metabolic syndrome 
when compared to the lowest CRP quartile and after adjustment for the mentioned confounders 
(P <0.0001). In multiple logistic regression analysis with age, gender, drinking, smoking, marital 
status, medication use, arthritis and all the components of metabolic syndrome, only cntral 




     In the present study, we found higher C-reactive protein concentrations among Mexican 
Americans with metabolic syndrome compared to individuals without the syndrome. We also 
observed higher prevalence of metabolic syndrome in Mexican Americans with elevated CRP 
concentrations. These results are consistent with the reports from previous studies which 




(12, 49 and 50). Using data from 8570 participants of NHANES III, Ford (50) found higher age 
adjusted prevalence of elevated CRP concentrations among subjects with metabolic syndrome 
compared to subjects without the syndrome (29% vs. 12%). Metabolic syndrome was defined 
according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP 
III). In 2005, Ye and colleges investigated the distribution of CRP and its association with 
metabolic syndrome among 3289 Chinese men and women who participated in Nutrition and 
Health of Aging Population in China. They defined metabolic syndrome based on NCEP ATP III
for Asian Americans and reported higher prevalence of metabolic syndrome among subjects with 
elevated CRP concentrations (12). 
     The present study also revealed significant associations between CRP and waist 
circumference, body mass index, triglyceride, HDL cholesterol, fasting plasma glucose 
concentrations and systolic blood pressure. The correlation coefficients were tronger among 
women compared to men. These associations were independent of age, education, income, 
language spoken at home, marital status, lifestyle factors, family history of diabetes, angina and 
stroke, medication use, arthritis and menopausal status in women. Consistent with these findings, 
Ford and colleges examined the distribution and correlates of CRP concentrations among 2205 
adult American women from NHANES 1999-2000. Using multiple linear regression they 
observed significant associations between CRP and waist circumference, tiglyceride and total 
cholesterol concentrations and systolic blood pressure (18). In the analysis of Nutrition and 
Health of Aging Population data in China, Ye and colleges observed significant associations 
between CRP, waist circumference and the elements of metabolic syndrome am ng 3289 
Chinese men and women. The correlation coefficients were calculated by Spearman partial 




were lower than correlation coefficients we calculated using multiple linear regression after 
adjustment for relevant continuous and categorical confounding variables. 
     We also observed that higher levels of CRP concentrations were associated with an increased 
risk of having central obesity, hypertriglyceridemia, reduced HDL cholesterol and metabolic 
syndrome. This association was independent of age, gender, alcohol intake, smoking, langua e 
spoken at home, marital status, arthritis and medication use. Subjects in the highest quartile of 
CRP were 9.9 times more likely, even after controlling for confounders, to have metabolic 
syndrome. In logistic regression analysis with age, gender, drinking, smoking, marital status, 
medication use, arthritis and all the five components of metabolic syndrome, central obesity had 
the largest odds ratio for having elevated CRP concentrations, suggesting tha  central obesity is 
mostly responsible for increased CRP levels among individuals with metabolic syndrome. 
Findings from analyzing national surveys are also in agreement with our results. Ford (50) in the 
analysis of data from 8570 participants of NHANES III observed the highest odds ratio fo  
having elevated CRP levels among individuals with abdominal obesity. Obesity is correlated 
with inflammatory responses, characterized by abnormal adipokines production and 
overproducing of some inflammatory markers (20, 51). Recent data indicate that obese adipose 
tissue is infiltrated by macrophages, which are responsible for the most part ofthe l cally 
produced tumor necrosis factor α (TNFα) and large amounts of interleukin 6 (IL-6) and 
inducible nitric oxide synthase expression (52, 53). IL-6 can increase plasma concentration of 
fibrinogen, plasminogen activator inhibitor 1 (PAI-1) and CRP (54). 
     Our study has some limitations. The cross-sectional nature of the study would not al ow us to 
establish causal relationships between metabolic syndrome risk factors and C-reactive protein. In 




sampled in NHANES and the small number of ‘other Hispanics’ in data set were not sufficient to 
be analyzed as a separate group.  
     To our knowledge, this is the first study to investigate the association between C-r active 
protein and metabolic syndrome in Mexican American adults using 8 years of continuous 
NHANES 1999-2006 data. The findings of the present study are derived from a representative 
sample of Mexican American adults in the United States and are applicable to this population. 
     In summary, we found higher C-reactive protein concentrations among Mexican Americans 
with metabolic syndrome. We also observed that higher levels of CRP concentrations were 
associated with an increased risk of having metabolic syndrome and its components. Considering 
the high prevalence of metabolic syndrome and low grade inflammation in Mexican Americans, 
they are at higher risk for developing cardiovascular disease and diabetes mellitus. To prevent or 
delay the development of these conditions, proper approaches for prevention, treatment and 
management of metabolic syndrome and/or chronic inflammation are necessary. Lifest le 
modifications, nutritional education, weight control programs, physical activity and 
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Table 5.1. Basic characteristics and metabolic risk factors among Mexican American adults aged 20-80 
years, NHANES 1999-2006* 
*HDL, high density lipoprotein; LDL, low density lipoprotein; SBP, systolic blood pressure; DBP, diastolic blood 
pressure. The means of all continuous variables and frequencies of all categorical variables were compared in men 
and women using SUDAAN’s t test and χ 2 test, respectively. Statistical significance was set at P <0.05. 
† Values are means (SEM) for continuous variables and percentages (SEM) for categorical variables. 
‡ Metabolic risk factors were defined according to IDF definition (31). ||Statin lipid lowering medications or anti-
inflammatory medications. § Significant difference between men and women. ¶ Unstable estimates.  
Variables 
 Total  Men  Women 
  n Mean or % (SEM)†   n Mean or % (SEM)   n Mean or % (SEM) 
Age (y) 3265 38.07 (0.52) 1794 37.08 (0.46) 1471 39.50 (0.67)§ 
Height (cm) 3223 165.05 (0.18) 1780 169.97 (0.25) 1443 157.88 (0.23)§ 
Weight (kg) 3203 76.56 (0.41) 1764 80.69 (0.59) 1439 70.57 (0.58) § 
Body mass index (kg/m2) 
< 18.5 (%) 
≥ 18.5 to < 25 (%) 
≥ 25 to < 30 (%) 































Waist Circumference (cm) 3139 95.02 (0.41) 1726 96.69 (0.55) 1413 92.62 (0.58)§ 
Fasting plasma glucose (mg/dl) 1421 104.16 (1.07) 789 104.91 (1.31) 632 103.08 (1.77) 
Total cholesterol (mg/dl) 1407 196.37 (1.47) 783 199.90 (1.91) 624 191.22 (2.00)§ 
HDL cholesterol (mg/dl) 1408 49.20 (0.48) 784 46.33 (0.50) 624 53.39 (0.69)§ 
LDL cholesterol (mg/dl) 1343 117.82 (1.21) 737 123.03 (1.54) 606 110.51 (1.57)§ 
Triglycerides (mg/dl) 1407 155.65 (6.12) 783 166.00 (8.70) 624 140.55 (6.86)§ 
SBP (mmHg) 2939 119.20 (0.51) 1631 120.56 (0.60) 1308 117.19 (0.66)§ 
DBP (mmHg) 2939 70.33 (0.31) 1631 70.97 (0.41) 1308 69.38 (0.37)§ 
C-reactive protein (mg/l) 
<1 mg/l (%) 
1-3 mg/l (%) 















































Metabolic risk factors (%)‡ 
Elevated triglyceride 
Reduced HDL cholesterol 
Elevated blood pressure 






































≥ 1 metabolic risk factor 
≥ 2 metabolic risk factor 








































0.82 (0.42) ¶ 



















Table 5.2.  Socio-economic and behavioral characteristics of the study population, NHANES 1999-
2006*  
Characteristics 
Total Men Women 
n % (SEM) n % (SEM) n % (SEM) 
Education (y) 
     <12  
      12  


























     Married 



















Language spoken at home  
     Only Spanish  
     Spanish > English  
     Spanish = English  
     English > Spanish  






































     Low  
     Middle 

























Smoking status  
     Never 
     Former 






















73.34 (1.31) § 
12.51 (1.09) § 
14.15 (0.87) § 
Alcohol intake (drink/mon) 
     <1  
     1-4  
     5-7  



























73.67 (1.16) § 
18.46 (1.10) § 
3.39 (0.56) § 
4.48 (0.61) § 
Physical activity (min/wk) 
     0  
     ≤ 150  

























*The frequencies of categorical variables were compared in men and women using SUDAAN’s χ 2 test. Statistical 
significance was set at P <0.05. 




Table 5.3. Geometric mean concentrations and the age adjusted prevalence of elevated CRP (mg/l) concentrations by presence and absence of 




Total Men Women Total  Men  Women  















































































































































































†Geometric mean concentrations of CRP were compared across the levels of m tabolic syndrome or its components and between men and women 
using SUDAAN’s t test. Metabolic syndrome was defined according to IDF definition (31). Estimates are unstable and should be interpreted 
cautiously (relative standard error of mean greater than 30%). 
‡Age adjusted prevalence of elevated CRP concentrations were compared across the levels of metabolic syndrome or its components and between 
men and women using SUDAAN’s t test.  





Table 5.4. The age adjusted prevalence of metabolic syndrome according to quartiles of CRP among 
Mexican American adults, NHANES 1999-2006*  
 Quartile of CRP  
P for trend Q1 (<0.75 mg/l) Q2 (0.75-1.75 mg/l) Q3 (1.76-3.74 mg/l) Q4 (>3.74 mg/l) 
Total (n=937) 26.98 (3.56)† 60.53 (4.04) 70.71 (3.54) 81.56 (4.00) < 0.0001 
Men (n=557) 28.24 (3.91) 61.17 (5.18) 70.77 (5.05) 75.15 (5.32)§ < 0.0001 
Women (n=380) 20.26 (5.55) 56.82 (7.63) 70.94 (6.25) 87.82 (3.70) < 0.0001 
*Metabolic syndrome was defined according to IDF definition (31):elevated triglyceride, ≥ 150 mg/dl or 
specific treatment for hypertriglyceridemia; reduced HDL cholesterol, < 40 mg/dl for men and <50 mg/dl 
for women or specific treatment for this lipid abnormality; elevated blood pressu e, systolic blood pressure 
≥ 130 mmHg, diastolic blood pressure ≥85 mmHg or treatment for previously diagnosed hypertension; 
elevated fasting plasma glucose ≥ 100 mg/dl or previously diagnosed type 2 diabetes; central obesity, waist 
circumference ≥ 90 cm for men and ≥ 80 cm for women. 





























Table 5.5. Correlation coefficients of log transformed CRP and the components of metabolic 
syndrome among Mexican American adults, NHANES 1999-2006*  
 
 BMI WC TG HDLc FPG SBP DBP 
All 0.59 0.60 0.44 -0.46 0.43 0.42 0.41§ 
Men 0.55 0.54 0.43 -0.42 0.41 0.41 0.39§ 
Women 0.64 0.69 0.50§ -0.53 0.48§ 0.51§ 0.51§ 
*BMI,  body mass index; WC, waist circumference; TG, triglyceride; HDLc, high density lipoprotein 
cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma 
glucose. SUDAAN’s regress procedure was used to determine the correlati n coefficients of log CRP 
with the components of metabolic syndrome after adjusting for age, income, alcohol intake, physical 
activity and levels of education, smoking, marital status, language spoken at home, arthritis, 
medication use, family history of diabetes, angina and stroke and menopausal stat in women.  
Except for the correlation coefficient of log CRP with TG, FPG, SBP and DBP in women and DBP in 





Table 5.6. Odds ratios and 95% confidence interval for metabolic syndrome and its components according to 
quartiles of CRP among Mexican American adults, NHANES 1999-2006*  
 
Metabolic syndrome or 
its components 
Quartile of CRP  
P for 
trend 
Q1 (<0.75 mg/l) Q2 (0.75-1.75 mg/l) Q3 (1.76-3.74 mg/l) Q4 (>3.74 mg/l) 

















































































*Odds ratios of having metabolic syndrome or its components were compared across the quartiles of CRP 
(the lowest quartile as reference group). The logistic regression model was adjusted for age, gender, alcohol 
intake and smoking in model 1 and further adjusted for marital status, language spoken at home, medication 
use and arthritis in model 2. Values are adjusted OR (95% CI). 
†Metabolic syndrome was defined according to IDF definition (31):elevated triglyceride, ≥ 150 mg/dl or 
specific treatment for hypertriglyceridemia; reduced HDL cholesterol, < 40 mg/dl for men and <50 mg/dl 
for women or specific treatment for this lipid abnormality; elevated blood pressu e, systolic blood pressure 
≥ 130 mmHg, diastolic blood pressure ≥85 mmHg or treatment for previously diagnosed hypertension; 
elevated fasting plasma glucose ≥ 100 mg/dl or previously diagnosed type 2 diabetes; central obesity, waist 






Table 5.7. Association between elevated CRP and elements of metabolic syndrome amng Mexican American adults*  
 
Characteristics 
Total (n=1440) Men (n=793) Women (n=647) 
OR (95% CI) P OR (95% CI) P OR (95% CI) P 
Central obesity 
   Yes 

















   Yes 

















   Yes 

















   Yes 
















Low HDL cholesterol 
   Yes 
















Age (y) 1.00 (0.98-1.03) 0.671 1.01 (0.98-1.04) 0.399 0.99 (0.96-1.02) 0.438 
Gender 
   Men 
















Drinking 0.99 (0.95-1.03) 0.672 0.99 (0.95-1.03) 0.579 1.02 (0.89-1.18) 0.737 
Smoking 
   Never 
   Former 






















   Married 

















   Yes 

















   Yes 



















*Metabolic syndrome components were defined according to IDF definition (31): hypertriglyce demia, ≥ 150 mg/dl or specific 
treatment for hypertriglyceridemia; reduced HDL cholesterol, < 40 mg/dl for men and <50 mg/dl for women or specific treatment 
for this lipid abnormality; hypertension, systolic blood pressure ≥ 130 mmHg, diastolic blood pressure ≥85 mmHg or treatment for 
previously diagnosed hypertension; hyperglycemia, glucose ≥ 100 mg/dl or previously diagnosed type 2 diabetes; central obesity, 










 Figure 5.1.  Geometric mean CRP concentrations by the number of components of 
metabolic syndrome in Mexican American men and women, NHANES 1999-2006. 




Chapter 6: Conclusion 
In the present study, I used data from the National Health and Nutrition Examination Survey 
(NHANES) 1999-2006, to determine the appropriate waist circumference cutoff values for 
diagnosis of central obesity in Mexican American adults and compared the prevalence of 
metabolic syndrome based on IDF definition with and without the modified waist circumference 
in Mexican Americans. I also examined the association between abdominal adiposity, measured 
by waist circumference and overall obesity, measured by body mass index with the components 
of metabolic syndrome including, triglyceride, blood pressure, fasting plasma glucose and HDL 
cholesterol in Mexican American adults and investigated the odds for developing metabolic 
syndrome risk factors according to quartiles of waist circumference in this population. To study 
the final objectives of the dissertation, I investigated the distribution of CRP and its association 
with metabolic syndrome in Mexican Americans and estimated the odds ratios for developing 
metabolic syndrome or its components (central obesity, hypertriglyceridemia, hyperglycemia, 
hypertension and low HDL cholesterol) according to quartiles of CRP in this populati n. 
     According to ROC curve analysis, the optimal waist circumference cutoff values with 
maximum sensitivity and specificity for predicting the presence of two or more metabolic risk 
factors and the shortest distance on the ROC curve was 95 cm for both men and women. The 
sensitivity and specificity of this cutoff were 66.7% and 60.4% in both genders, respectively. 
Since IDF criteria requires the presence of central obesity for the diagnosis of metabolic 
syndrome, we justified to choose a cutoff point that obtains at least 80% sensitivity even if it 
causes a significant decrease in specificity. Therefore, the appropriate wais  circumference to 
predict two or more metabolic risk factors in Mexican Americans with 80% sensitivity was 90 




After applying the modified waist circumference of 90 cm, we noticed 34% reduction in the 
prevalence of central obesity in women (82.5% to 54.2%). The age adjusted prevalence of 
metabolic syndrome in women also decreased from 64.8% to 37.8%. 
      Waist circumference and BMI were highly correlated in both men and women (r= 0.935, 
n=777 in men and r= 0.895, n=619 in women; P <0.0001 for both). All correlation coefficients 
of WC and BMI with the components of metabolic syndrome were significant among men (P 
<0.05). In women, WC and BMI were significantly correlated with HDL cholesterol. In both 
genders the correlation coefficients were stronger between WC and metabolic risk factors than 
those of BMI; however the reverse pattern was noticed in correlation between WC and BMI with 
HDL cholesterol in women. The Odds ratios of metabolic syndrome risk factors increased from 
1st to 4th quartile of waist circumference (P for trend <0.001 for all). Compared with individuals 
in the lowest WC quartile, those in the highest quartile had an OR of 4.18 (95% CI: 1.96, 8.93) 
for elevated triglyceride, 3.50 (95% CI: 1.69, 7.26) for elevated blood pressure, 5.71 (95% CI: 
3.24, 10.09) for reduced HDL cholesterol and 2.34 (95% CI: 1.32, 4.14) for elevated fasting 
plasma glucose, respectively, after adjustment for relevant confounders (P < 0.001 for all). These 
subjects were also 9 times more likely (95% CI: 5.00, 14.96) to have 2 or more metabolic risk 
factors when compared to the lowest WC quartile and after adjustment for the mentioned 
confounders (P <0.0001). 
     The geometric mean concentrations of CRP were significantly higher among subject  with 
metabolic syndrome than those who did not have metabolic syndrome (2.31 mg/l vs. 0.81 mg/l, 
P <0.01). Participants with central obesity, hypertriglyceridemia, hypertension and reduced HDL 
cholesterol also had higher levels of CRP concentrations than subjects without those conditions 




metabolic syndrome than those without the syndrome (42.7% vs. 17.2%, P <0.01). The age 
adjusted prevalence of metabolic syndrome increased from 26.9% to 81.6% as the CRP 
concentrations increased, P <0.0001. The increment pattern was observed in both genders across 
the CRP quartiles. C-reactive protein was significantly associated with almost all the elements of 
metabolic syndrome (except for diastolic blood pressure). All correlation coefficients were 
stronger among women than men.  
     The Odds ratios of having metabolic syndrome or its components increased across the CRP 
quartiles. Individuals with highest CRP concentrations were 9.9 times more likely (95% CI: 4.53, 
16.63) to have metabolic syndrome when compared to the lowest CRP quartile and after 
adjustment for age, gender, alcohol intake, smoking (model 1), marital status, langage spoken at 
home, medication use and arthritis (model 2) (P <0.0001). In multiple logistic regression analysis 
with age, gender, drinking, smoking, marital status, medication use, arthritis and all the 
components of metabolic syndrome, only central obesity and gender were significant predictors 
of elevated CRP concentration, suggesting that central obesity is mostly responsible for 
increased CRP levels among individuals with metabolic syndrome. 
     The present study has some limitations. The cross-sectional nature of the study would not 
allow establishing causal relationships between metabolic syndrome risk factors nd waist 
circumference or metabolic syndrome and C-reactive protein. In addition, the results are not 
applicable to all Hispanics as only Mexican Americans were over sampled in NHANES and the 
small number of ‘other Hispanics’ in data set were not sufficient to be analyzed as a separate 
group.  
     To our knowledge, this is the first study to investigate the appropriate waist circumference 




adults. In addition, it is the first study to examine the association between abdominal adiposity 
and overall obesity with the components of metabolic syndrome and the associations be ween 
CRP and metabolic syndrome in Mexican Americans using 8 years of continuous NHANES 
1999-2006 data. The findings of the present study are derived from a representative sample of 
Mexican American adults in the United States and are applicable to this population. 
The results from this study will contribute in:  
• Understanding the importance of appropriate assessment of central obesity in screening 
metabolic syndrome 
• Providing practical guidance in identifying individuals with metabolic syndrome 
• Understanding the association between waist circumference and metabolic risk factors in 
Mexican American adults   
• Emphasizing the importance of central obesity in increasing risk of having metabolic 
abnormalities 
• Understanding the association between C-reactive protein and metabolic syndrome in 
Mexican American adults   
 
     As current CRP cutoff values are derived from European and European American population 
studies, future research is needed to evaluate the appropriateness of these thresholds in predicting 
metabolic or CVD risk in other ethnic groups such as Hispanic Americans, African Americans 
and Native Americans. Nationwide studies to investigate the ethnic differences i  CRP 
distribution and its association with metabolic syndrome are needed. Further research should also 
investigate the appropriate body mass index and waist circumference cutoff values in predicting 
metabolic syndrome or CVD risk among different ethnic groups such as African Americans, 
Middle Eastern and All Hispanic populations.  
     Considering the high prevalence of metabolic syndrome, central obesity and low grade 




disease and diabetes mellitus. To prevent or delay the development of these conditions, 
multifaceted strategies for prevention, treatment and management of obesity, m tabolic 
syndrome and/or chronic inflammation are necessary. Lifestyle modifications, nutritional 
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